



UNIVERSITY OF TORONTO
LIBRARIES

 **CPOJ**
ISSN: 2561-987X

REVIEW ARTICLE

Canadian Prosthetics & Orthotics Journal

All articles are permanently available online to the public without restrictions or subscription fees. They are free to be used, cited, and distributed, provided that appropriate acknowledgment is included. Authors retain the copyright of their original contributions and grant the Canadian Online Publication Group (COPG) a license to publish the article and identify itself as the original publisher. CPOJ articles are licensed under the Creative Commons Attribution 4.0 International License.

CPOJ Website: <https://jps.library.utoronto.ca/index.php/cpoj/index>

Editorial Office: cpoj@online-publication.com

ISSN: 2561-987X

CPOJ is a member of, and subscribes to the principles of, the Committee on Publication Ethics (COPE). CPOJ articles are freely accessible on PubMed Central® (PMC).



VOLUME 8, ISSUE 1



2025

REVIEW ARTICLE

WOUND MANAGEMENT, HEALING, AND EARLY PROSTHETIC REHABILITATION: PART 3 - A SCOPING REVIEW OF CHEMICAL BIOMARKERS

Williams-Reid H¹, Johannesson A², Buis A^{1*}¹ Department of Biomedical Engineering, Faculty of Engineering, University of Strathclyde, Glasgow, Scotland.² Össur Clinics EMEA, Stockholm, Sweden.

ABSTRACT

BACKGROUND: Poor post-amputation healing delays prosthetic fitting, adversely affecting mortality, quality of life, and cardiovascular health. Current residual limb assessments are subjective and lack standardized guidelines, emphasizing the need for objective biomarkers to improve healing and prosthesis readiness assessments.

OBJECTIVE(S): This review aimed to identify predictive, diagnostic, and indicative chemical biomarkers of healing of the tissues and structures found in the residual limbs of adults with amputation.

METHODOLOGY: This scoping review followed Joanna Briggs Institute (JBI) and PRISMA-ScR guidelines. Searches using the terms “biomarkers,” “wound healing,” and “amputation” were performed across Web of Science, Ovid Medline, Ovid Embase, Scopus, Cochrane, PubMed, and CINAHL databases. Inclusion criteria were: 1) References to chemical biomarkers and healing; 2) Residuum tissue healing; 3) Repeatable methodology with ethical approval. Included articles were evaluated for quality of evidence (QualSyst tool) and level of evidence (JBI classification). Sources were categorized by study (e.g., randomized controlled trial or bench research), wound (diabetic, amputation, other), and model (human, murine, other) type. Chemical biomarkers repeated across study categories, and quantification methods were reported on.

FINDINGS: From 3,306 titles and abstracts screened, 646 underwent full-text review, and 203 met the criteria for data extraction, with 76% classified as strong quality. 38 chemical biomarkers were identified across 4 to 50 sources, with interleukins (predictive, indicative, and diagnostic) and HbA1c (predictive) most prevalent, appearing in 50 and 48 sources, respectively. Other biomarkers included predictive blood markers (e.g., cholesterol, white blood cell counts), indicative growth factors, bacteria presence (predictive), proteins (predictive, indicative, and diagnostic, e.g., matrix metalloproteinases), and cellular markers (indicative and diagnostic, e.g., Ki-67, alpha-smooth muscle actin [α -SMA]).

CONCLUSION: Predictive biomarkers identify comorbidities that may hinder healing, aiding in pre-amputation risk assessment for poor recovery. Indicative biomarkers monitor key biological healing processes, such as angiogenesis (the formation of new blood vessels), wound contraction, and inflammation. Diagnostic biomarkers provide direct insights into tissue composition and cellular-level healing. Integrating these biomarkers into post-amputation assessments enables continuous monitoring of the healing process while accounting for comorbidities, enhancing the objectivity of post-surgical healing management and ensuring more effective, personalized rehabilitation strategies.

INTRODUCTION

1: OVERALL RATIONALE, AIMS, AND OBJECTIVES

A wound is defined as damage to biological tissue,¹ encompassing various forms, including deep tissue injuries

associated with prolonged prosthesis use and the surgical site resulting from amputation. The wound healing process is a complex biological process involving four interlinked phases: hemostasis, inflammation, proliferation, and tissue remodeling.²⁻⁴ This process requires intricate cellular coordination, rendering it vulnerable to impairment that can result in a stalled (also known as chronic or non-healing) wound.⁵ Amputation surgical sites, however, do not always heal optimally, instead experiencing complications such as infection, pain, wound dehiscence, stitch abscesses, tissue necrosis, and poor residual limb formation.^{6,7} These

ARTICLE INFO

Received: July 12, 2024

Accepted: February 12, 2025

Published: February 21, 2025

CITATION

Williams-Reid H, Johannesson A, Buis A. Wound management, healing, and early prosthetic rehabilitation: Part 3 - A scoping review of chemical biomarkers. *Canadian Prosthetics & Orthotics Journal*. 2025; Volume 8, Issue 1, No.1.

<https://doi.org/10.33137/cpoj.v8i1.43717>

KEYWORDS

Amputation; Scoping Review; Wound Healing; Surgical Site Healing; Chemical Biomarkers; Chemical Markers of Healing; Residuum Healing; Residual Limb Healing; Wound Management; Early Prosthetic Rehabilitation

Please refer to the end of the article for a list of **Abbreviations & Acronyms**.

* CORRESPONDING AUTHOR:

Professor Arjan Buis, PhD

Department of Biomedical Engineering, Faculty of Engineering, University of Strathclyde, Glasgow, Scotland.

E-Mail: arjan.buis@strath.ac.ukORCID ID: <https://orcid.org/0000-0003-3947-293X>

complications stall healing and, in severe cases, necessitate revision surgeries or re-amputation.⁶

Despite their critical role in preventing complications like re-amputation, wound healing assessments remain subjective.⁸ This is particularly significant for individuals with major lower limb amputation, defined as amputation through or proximal to the ankle, whose readiness for prosthetic rehabilitation depends on the health and healing of their residual limb. Early prosthetic fitting improves mobility, ambulation, and daily functioning,⁹⁻¹¹ whilst increased costs and elevated three-year post-amputation mortality rates are associated with delays or failure to provide timely prosthetic interventions.^{10,11} However, current evaluations of the residual limb post-amputation rely on clinical judgement, lacking standardized guidelines or objective metrics.^{8,12,13} While factors like wound healing, pain management, and limb volume are considered, they are not consistently quantified. Additionally, debates over rehabilitation practices promoting residual limb healing, such as the use of rigid versus soft immediate post-operative dressings,^{14,15} further highlight inconsistencies in clinical approaches.

There is a need for objective measures, such as biomarkers, to evaluate wound healing and thus readiness for prosthetic fitting. Biomarkers, as defined by the United States Food and Drug Administration (U.S. FDA) as measurable indicators of biological processes or responses to treatment,¹⁶ provide a means to minimize the subjectivity of current practices. However, their application in early-stage post-amputation healing remains largely unexplored.^{8,17,18} To address this research need, a scoping review was developed and implemented with the following aim:

Identify predictive, diagnostic, and/or indicative biomarkers (physical, chemical, or other) of healing of the tissues and structures found in the residual limbs of adults with amputation.

To meet this aim, the following objectives were compiled:

- 1) Collate and synthesize the reported definitions of healing and non-healing in the literature investigating healing of the tissues and structures found in the residual limbs of adults with amputation.
- 2) Identify and collate physical biomarkers predictive, diagnostic, and/or indicative of healing repeated in sources investigating healing of the tissues and structures found in the residual limbs of adults with amputation.
- 3) Identify and collate chemical biomarkers predictive, diagnostic, and/or indicative of healing repeated in sources investigating healing of the tissues and structures found in the residual limbs of adults with amputation.
- 4) Assess the quality and levels of evidence from sources investigating the healing of the tissues and structures found

in the residual limbs of adults with amputation.

In the aim, biomarkers are classified by their nature and function. Physical biomarkers are measurable attributes of the wound or tissue itself, such as wound pH or temperature, whilst chemical biomarkers are molecules found in biological tissue or fluids (e.g., sweat, sebum, saliva, and blood) that signal biological processes such as cytokines. Functionally, predictive biomarkers assess the likelihood of a healing state or treatment response, while diagnostic biomarkers definitively confirm healing progression or status. Indicative biomarkers suggest the presence of a condition or physiological state but are not definitive.

2: PART 3 RATIONALE, AIMS, AND OBJECTIVES

This article (Part 3) addresses Objective 3 and is the final instalment in a three-part series examining Objectives 1 through 3. [Part 1](#) highlighted significant gaps in defining healing and non-healing, emphasizing the need for an amputation-specific wound healing assessment scale incorporating objective measures like biomarkers.¹⁷

[Part 2](#) focused on physical biomarkers quantifying macro-level physiological properties.¹⁸ While useful and easily non-invasively measured, these biomarkers, such as hemodynamic and oxygenation measures, often indicate changes resulting from cellular healing processes rather than directly representing the healing process itself. For example, wound temperature changes (a physical biomarker) may reflect inflammation, immune responses, vasodilation, and tissue metabolism.¹⁹⁻²¹ In contrast, chemical biomarkers like interleukins and C-reactive protein directly signal inflammatory responses²² and serve as more precise diagnostic indicators of healing mechanisms.

Currently, poor healing is defined by clinical endpoints like wound dehiscence or necrotic tissue formation.¹⁷ Chemical biomarkers provide earlier insights into the healing process, allowing evaluation of treatments and rehabilitation programs. For instance, serum levels of matrix metalloproteinase 2 (MMP-2) and MMP-7 can predict wound dehiscence,^{23,24} as these MMPs support extracellular matrix remodeling, which is essential for tensile skin strength.²⁵

Chemical biomarkers provide diagnostic insights into healing because they are intrinsic components of the healing process, with their levels directly reflecting specific healing mechanisms. For instance, the Ki-67 protein functions as a marker of cellular proliferation in human cells.^{26,27} The proliferation of fibroblasts, endothelial cells, and keratinocytes is vital for cutaneous wound healing, as it constitutes the third stage of the four-step healing process.²⁸ To demonstrate the indicative and diagnostic power of Ki-67 in healing, Escuin-Ordinas et al.²⁹ observed that diabetic wounds with higher wound closure scores exhibited significantly greater numbers of Ki-67-positive

cells. Similarly, collagen, another chemical biomarker, is embedded in essential healing mechanisms. It aids healing by attracting fibroblasts and promoting new collagen formation within the wound bed.³⁰ Thus, chemical biomarkers offer sensitive, specific measures of healing, improving understanding of post-amputation recovery and guiding rehabilitation. Therefore, the aim of this review was to:

Identify predictive, diagnostic, and/or indicative chemical biomarkers of healing in the tissues and structures found in the residual limbs of adults with amputations.

To achieve this aim, the following objectives were established:

- 1) Identify and compile chemical biomarkers that are predictive, diagnostic, and/or indicative of healing as reported in sources investigating the tissues and structures of residual limbs in adults with amputations.
- 2) Identify and summarize the techniques used to quantify these chemical biomarkers in studies focused on the healing of tissues and structures in residual limbs of adults with amputations.
- 3) Assess the quality and levels of evidence in sources investigating the healing of tissues and structures found in the residual limbs of adults with amputations.

METHODOLOGY

The detailed methodology and rationale for this review have been outlined previously in Parts 1¹⁷ and 2.¹⁸ Briefly, the review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) checklist^{31,32} and the Joanna Briggs Institute (JBI) guidelines.³³⁻³⁶ Data were managed using Excel Version 2303 (Microsoft, Washington, USA) on Windows 11 Version 22H2 (Microsoft, Washington, USA).

1: INCLUSION CRITERIA AND SEARCH STRATEGY

Finalized search terms, based on the terms “biomarker”, “amputation”, and “wound healing”, were applied to Web of Science, MEDLINE (Ovid), Embase (Ovid), Scopus, Cochrane, PubMed, and CINAHL databases. In stage one of screening titles and abstracts were screened using primary inclusion criteria: references to biomarkers of healing and publications from 2017 onward. Given the limited exploration of chemical biomarkers in early-stage post-amputation healing,^{8,17,18} the inclusion criteria were broadened to cover tissues and structures biologically comparable to those in a residuum (e.g., skin, muscles, tendons, ligaments, bone, peripheral nervous system, and vasculature). In the second screening phase of full-texts, additional criteria were introduced, including reproducible methodologies, clear ethical approval (where applicable),

and participants aged 18 years or older for human studies. Bench research using in vitro, in silico, or murine models was considered for inclusion to capture biomarkers requiring cell or tissue samples which are ethically easier to obtain in these contexts. Murine models were considered suitable due to sufficient genetic similarities to humans and common use in biological research.³⁷ Studies from all contexts and regions were considered if available in English. Search results were managed in EndNote 20 (Version 20.2.1, Clarivate, 2021), where duplicates were removed.

2: DATA EXTRACTION, ANALYSIS AND PRESENTATION

Using a pre-defined data extraction tool (Part 1, Appendix A¹⁷), data (including chemical biomarkers and study characteristics) was extracted from sources that passed both screening rounds. Study quality and evidence levels were evaluated using the QualSyst tool³⁸ and JBI levels of evidence³⁹ respectively. All extracted data are openly accessible in the review's dataset.⁴⁰

Included sources were categorized by study (randomized controlled trial, case-controlled, observational, or bench research), wound (diabetic, amputation, or other), and model (human, murine, or other) type. Chemical biomarkers that were observed more than once within and across study categories are reported on. These repeated chemical biomarkers are represented in tabular form and analyzed in comparison with existing literature for their indicative, predictive, and/or diagnostic potential in healing assessment. The review emphasizes recurring biomarkers, assuming their repeated observation indicates a stronger evidence base for the biomarker's use, thus supporting future research. Descriptive results section (section 3: Measurement Techniques of The Repeated Chemical Biomarkers) and discussion section (section 2.2: Quantification Techniques) summarize biomarker quantification methodologies, offering additional context for the future use of the biomarkers in residual limb healing management.

RESULTS

1: OVERALL RESULTS

1.1: Search Strategy Results

As disseminated in Part 1,¹⁷ the search strategy identified 7,041 sources for screening. Of these, 3,735 were duplicates and were subsequently removed (Part 1 - PRISMA diagram). From the remaining 3,306 articles screened at the title and abstract level, 646 met the criteria for full-text screening. 219 articles satisfied the inclusion criteria and were selected for data extraction. Primary reasons for exclusion included unclear methodologies, lack of ethical approval, and review article study type. Of the 219 included sources, 203 reported on chemical biomarkers and are therefore the focus of this Part 3 review.

1.2: Quality and Levels of Evidence

The quality assessment of the included sources revealed a strong emphasis on high-quality quantitative research. The majority of included sources (155 out of 203, or 76%)^{29,41-194} were classified as being of strong quality. An additional 40 sources¹⁹⁵⁻²³⁴ were rated as good quality, while only 8 sources²³⁵⁻²⁴² fell into the adequate quality category. None of the sources were categorized as having limited quality.

Contrastingly levels of evidence of the included sources demonstrated greater variability. In the Prognosis category, 29 studies were classified as level 1.b, representing the second-highest evidence level, while only 3 studies^{64,68,173} fell into level 5.c, the lowest evidence tier (Table 1). Conversely, within the Effectiveness category, a minimal number of studies were rated at the higher evidence levels, with 1 study²⁰⁷ classified as 1.b and 12 studies^{75,109,170,176,182,199,204,205,210,221,222,241} as 1.c (Table 1). However, the majority of studies in this category, (96 studies) were assigned to level 5.c. This prevalence of level 5.c can be attributed to the significant number of bench research studies (Study Categories 9 to 13 in Table 2), which are considered the lowest evidence level.

For a comprehensive discussion of the quality and evidence levels of all 219 sources that satisfied the inclusion criteria for the overall review aim, refer to Part 1.¹⁷

1.3 Study Types and Characteristics

Of the 203 included sources, observational and bench research studies accounted for the largest proportions, comprising 89 and 97 sources, respectively (Table 2). In contrast, only 13 sources were randomized controlled trials (RCTs), and 6 were case-controlled studies.

In Categories 1 to 8 (Table 3), studies involving human participants featured sample sizes ranging from just 1 participant in a case-controlled study¹⁴⁵ to 11,943,000 participants in an observational retrospective study.¹⁴⁰ This large sample size is attributed to the examination of annual rates of hemoglobin A1c (HbA1c) testing and major leg amputations among Medicare patients with diabetes spanning from 2003 to 2012 across 306 hospital referral regions in the USA.¹⁴⁰ Of the 106 sources, 95 provided gender information, with median male representation within each category ranging from 50% to 71% of participants (Table 3).

Median mean participant ages exceeded 58 years across all study categories, with reported means ranging from 28.8²⁰⁴ to 77.3²²⁰ years. Among the human participant studies, 68 investigated diabetic wounds, 27 focused on amputations (some resulting from diabetic wounds), and 20 explored other wound types (Table 3). Examples of the latter included skin wounds,^{50,175} lower limb mangled extremities,¹⁵⁴ and infected wounds.¹²⁸

Similarly, to the human participant studies, bench research predominantly used male subjects and focused on diabetic wounds. Of the murine models employed in 81% (79 sources) of the bench research studies, 56 sources utilized all male rats/mice, 6 sources used all female, and the remaining 17 sources used both or did not specify gender (Table 2). In place of murine models, the remaining bench research studies utilized cell lines and tissue samples (15 sources^{41,42,45,53,95,98,108,132,135,139,151,166,196,237,242}), a mathematical model (1 source⁷⁶), and a gene expression dataset (1 source¹⁵⁶). Categories 9 to 11 (80 sources; Table 2) specifically investigated diabetic wounds, while 7,^{55,101,141,148,184,211,214} 4,^{64,161,163,173} 2,^{87,155} and 4,^{53,139,166,242} sources explored skin wounds, traumatic injuries, sciatic nerve injuries, and wound/scratch assays (a type of cell-based wound model), respectively.

2: REPEATED CHEMICAL BIOMARKERS

Of 38 identified repeated chemical biomarkers (Table 4), interleukins (ILs) were the most frequently reported, appearing in 50 sources (25% of 203 included sources). This was followed by glycated hemoglobin (HbA1c) and vascular endothelial growth factor (VEGF), which were utilized in 48 and 39 sources, respectively. Other notable biomarkers included C-reactive protein (CRP) and tumor necrosis factor (TNF), each reported in 34 studies, and albumin, which was employed in 31 sources. Biomarkers such as matrix metalloproteinases (MMPs), collagen, and creatinine were observed in 10% to 14% of sources, whereas less frequently reported biomarkers, including zinc and myeloperoxidase (MPO), were present in only 2% to 5% of studies.

The distribution of repeated biomarkers across study categories (Table 2 and Table 4) underscores the relationship between study design and biomarker prevalence. For instance, 27 of the 38 biomarkers were identified in bench research studies (Study Categories 9 to 13) which primarily use murine models (79 of 97 bench research included sources), indicating that such study types provide more detailed chemical biomarker data. In contrast, biomarkers exclusively observed in human participant studies only (Study Categories 1 to 8) include HbA1c, CRP, white blood cells (WBC), hemoglobin (Hb), cholesterol, erythrocyte sedimentation rate (ESR), fasting blood sugar, neutrophils and lymphocytes, platelets, zinc, and hemoglobin, all of which are typically routine blood biomarkers used to assess participants' general health status. Additionally, the high prevalence of diabetic wound studies (explored in Study Categories 1 to 3, 6, and 9 to 11) is reflected in the extensive use of HbA1c, which is clinically utilized for diabetes diagnosis.²⁴³

Table 1: Levels of evidence of the 203 included articles ranked using the JBI (Joanna Briggs Institute) Levels of Evidence (44) (NA = not applicable).

| Evidence Level | JBI Evidence Level Study Categories | | |
|----------------|---|------------------------------------|---|
| | Effectiveness | Diagnosis | Prognosis |
| 1.a | 0 | 0 | 0 |
| 1.b | 1 (207) | 7 (67, 73, 85, 130, 154, 217, 239) | 29 (47, 61, 69, 72-74, 85, 86, 90, 115, 116, 120, 123, 130, 138, 144, 149, 154, 157, 159, 162, 169, 175, 197, 217, 225, 234, 239, 240) |
| 1.c | 12 (75, 109, 170, 176, 182, 199, 204, 205, 210, 221, 222, 241) | NA | NA |
| 1.d | 0 | NA | NA |
| 2.a | 0 | 0 | 0 |
| 2.b | 0 | 0 | 0 |
| 2.c | 0 | NA | NA |
| 2.d | 0 | NA | NA |
| 3.a | 0 | 0 | 0 |
| 3.b | 1 (104) | 0 | 42 (43, 44, 46, 58, 60, 62, 63, 65, 67, 77-79, 81-84, 92, 94, 100, 102, 106, 128, 129, 131, 133, 134, 140, 142, 147, 150, 160, 168, 171, 172, 179, 181, 185, 200, 220, 228, 230, 235) |
| 3.c | 3 (89, 203, 217) | NA | NA |
| 3.d | 3 (97, 127, 195) | NA | NA |
| 3.e | 30 (43, 46, 48, 50, 52, 57, 59, 62, 67, 73, 74, 85, 90, 94, 99, 129, 131, 143, 144, 146, 149, 164, 175, 185, 189, 198, 224, 236, 238, 240) | NA | NA |
| 4.a | 0 | 0 | 0 |
| 4.b | 0 | 0 | 2 (97, 152) |
| 4.c | 0 | NA | NA |
| 4.d | 1 (145) | NA | NA |
| 5.a | 0 | 0 | 0 |
| 5.b | 0 | 0 | 0 |
| 5.c | 96 (29, 41, 42, 45, 49, 51, 53-56, 64, 66, 68, 70, 71, 76, 80, 87, 88, 91, 93, 95, 96, 98, 101, 103, 105, 107, 108, 110-114, 117-119, 121, 122, 124-126, 132, 135-137, 139, 141, 148, 151, 153, 155, 156, 158, 161, 163, 165-167, 174, 177, 178, 180, 183, 184, 186-188, 190-194, 196, 201, 202, 206, 208, 209, 211-216, 218, 219, 223, 226, 227, 229, 231-233, 237, 242) | 3 (68, 126, 194) | 3 (64, 68, 173) |

Table 2: Summary of the study types of all 203 included sources utilizing chemical biomarkers. The sources are categorized by study type, wound type, and model type, with reference numbers provided for each category as used throughout the review.

| Study Type | | Category Reference Number | Number (%) of Included Sources | Included Source References | |
|-----------------------------|-----------------|---------------------------|--------------------------------|--|---|
| Randomized Controlled Trial | | 1 | 13 (6%) | (75, 109, 170, 176, 182, 199, 204, 205, 207, 210, 221, 222, 241) | |
| Case-Controlled Study | | 2 | 6 (3%) | (97, 127, 131, 145, 152, 195) | |
| Observational | Prospective | Diabetic Wounds | 3 | 29 (14%) | (47, 48, 59, 61, 62, 69, 72-74, 89, 90, 115, 120, 123, 138, 143, 144, 146, 157, 197, 198, 203, 217, 224, 225, 234, 236, 238, 239) |
| | | Amputation | 4 | 8 (4%) | (57, 85, 130, 149, 159, 162, 169, 240) |
| | | Other Wounds | 5 | 6 (3%) | (50, 52, 86, 99, 154, 175) |
| | Retrospective | Diabetic Wounds | 6 | 18 (9%) | (58, 63, 67, 81, 84, 92, 94, 100, 133, 134, 164, 171, 172, 179, 181, 185, 230, 235) |
| | | Amputation | 7 | 14 (7%) | (43, 44, 46, 60, 79, 83, 129, 140, 142, 150, 160, 189, 200, 220) |
| | | Other Wounds | 8 | 12 (6%) | (65, 77, 78, 82, 102, 104, 106, 116, 128, 147, 168, 228) |
| Bench Research | Diabetic Wounds | Rat Models | 9 | 25 (12%) | (51, 54, 70, 88, 96, 110, 111, 113, 117, 121, 122, 125, 136, 137, 165, 167, 174, 186, 191, 218, 223, 229, 231-233) |
| | | Mouse Models | 10 | 41 (20%) | (29, 49, 56, 66, 71, 80, 91, 93, 103, 105, 107, 112, 114, 118, 119, 124, 126, 153, 158, 177, 178, 180, 183, 187, 188, 190, 192-194, 201, 202, 206, 208, 209, 212, 213, 215, 216, 219, 226, 227) |
| | | Other Models | 11 | 14 (7%) | (41, 42, 45, 68, 76, 95, 98, 108, 132, 135, 151, 156, 196, 237) |
| | Other Wounds | Rat/Mouse Models | 12 | 13 (6%) | (55, 64, 87, 101, 141, 148, 155, 161, 163, 173, 184, 211, 214) |
| | | Other Models | 13 | 4 (2%) | (53, 139, 166, 242) |

Table 3: The characteristics (wound type, sample size, gender distribution, and age) of the included sources involving human participants (Study Categories 1 to 8; **Table 2**). Note that for wound type some sources fall under more than one wound type. For example, Norvell et al.¹⁴² (a Category 7 source) investigated wound healing of lower limb amputation due to diabetes or peripheral arterial disease. The notation “No. (%) of references” indicates the number and percentage of sources that provide characteristic information relative to the total number of sources within that category (T.G. = treatment groups; C.G. = control groups; No. = number; NA = not applicable).

| | Study Category | | | | | | | |
|---|--|-----------------------------|--|---------------------------------------|---------------------------|--|---|--|
| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| Wound Type Totals | | | | | | | | |
| Diabetic | 10 (75, 170, 176, 182, 199, 205, 207, 221, 222, 241) | 5 (127, 131, 145, 152, 195) | 29* | 1 (159) | 0 | 18* | 5 (83, 129, 140, 142, 200) | 0 |
| Amputation | 1 (109) | 4 (97, 131, 145, 152) | 0 | 8* | 0 | 0 | 14* | 0 |
| Other | 2 (204, 210) | 0 | 0 | 0 | 6* | 0 | 0 | 12* |
| Sample Size Totals | | | | | | | | |
| Range (Min-Max) | 15-200 | 1-120 | 4-684 | 10-556 | 5-735 | 48-1032 | 46-11943000 | 45-637 |
| Median | 33 | 20 | 57 | 21 | 18 | 148 | 205 | 125 |
| No. (%) of References | 13 (100%) | 6 (100%) | 29 (100%) | 8 (100%) | 6 (100%) | 18 (100%) | 14 (100%) | 12 (100%) |
| Sample Gender (% Male) Totals | | | | | | | | |
| Range (Min-Max) | 40%-82% | 0%-100% | 33%-91% | 55%-100% | 20%-79% | 44%-85% | 45%-99% | 54%-82% |
| Median | 63% | 50% | 63% | 64% | 62% | 64% | 71% | 67% |
| No. (%) of References | 11 (85%) (109, 170, 176, 182, 199, 204, 205, 207, 210, 222, 241) | 6 (100%) | 26 (90%) (47, 48, 59, 61, 62, 72-74, 89, 90, 115, 120, 123, 138, 143, 144, 146, 157, 197, 198, 203, 217, 224, 225, 234, 239) | 8 (100%) | 4 (67%) (52, 86, 99, 175) | 15 (83%) (58, 63, 67, 81, 84, 92, 94, 100, 164, 171, 172, 181, 185, 230, 235) | 14 (100%) | 11 (92%) (65, 77, 78, 82, 102, 104, 106, 116, 128, 147, 168) |
| Sample Mean Age (Years) Total | | | | | | | | |
| Range (Min-Max) | T.G.: 40.6-69.0; C.G.: 28.8-64.7 | 60.2-65.0 | 47.4-73.4 | 49.0-74.0 | NA | 54.5-72.5 | 38.0-77.3 | 56.0-74.0 |
| Median | T.G. 58.1; C.G.: 58.9 | 61.5 | 59.5 | 65.2 | NA | 61.2 | 66.7 | 72.0 |
| No. (%) of References | 12 (92%) (75, 109, 170, 176, 182, 199, 204, 205, 207, 210, 222, 241) | 3 (50%) (97, 127, 145) | 27 (93%) (47, 48, 59, 61, 62, 69, 72-74, 89, 90, 115, 120, 123, 138, 143, 144, 146, 157, 197, 198, 203, 217, 224, 225, 234, 239) | 6 (75%) (85, 149, 159, 162, 169, 240) | NA | 16 (89%) (58, 63, 67, 81, 84, 92, 94, 100, 133, 134, 164, 171, 181, 185, 230, 235) | 12 (86%) (43, 46, 60, 83, 129, 140, 142, 150, 160, 189, 200, 220) | 8 (67%) (65, 77, 78, 102, 104, 106, 147, 168) |
| Sample Age Range (Years) Total | | | | | | | | |
| Range (Min-Max) | NA | 35-94 | 20-89 | 23-87 | 28-88 | 23-100 | 26-96 | 22-96 |
| No. (%) of References | NA | 3 (50%) (131, 152, 195) | 11 (38%) (48, 61, 69, 90, 115, 138, 143, 198, 203, 217, 225) | 3 (38%) (57, 85, 159) | 4 (67%) (52, 86, 99, 175) | 6 (33%) (63, 84, 94, 133, 134, 235) | 2 (14%) (43, 129) | 1 (8%) (147) |
| Sample Median Age (Years) Totals | | | | | | | | |
| Range (Min-Max) | NA | NA | NA | NA | NA | NA | 47.0-62.0 | 31.0-71.2 |
| Median | NA | NA | NA | NA | NA | 72.5 | 54.5 | 68.4 |
| No. (%) of References | NA | NA | NA | NA | NA | 1 (6%) (172) | 2 (14%) (44, 79) | 3 (25%) (82, 116, 128) |

*References are provided in Table 2.

Table 4: A comprehensive breakdown of the repeated chemical biomarkers. A biomarker was considered "repeated" if it was used in more than one source within a study category and appeared in more than one study category. The occurrence of these biomarkers in the 203 included sources is presented, along with their representation across the various study categories (**Table 2**; freq. = frequency; ILs = interleukins; HbA1c = glycated hemoglobin; VEGF = vascular endothelial growth factor; CRP = C-reactive protein; TNF = tumor necrosis factor; TGF = transforming growth factor; WBC = white blood cells; CD = cluster of differentiation; Hb = hemoglobin; α -SMA = alpha-smooth muscle actin; MMPs = matrix metalloproteinases; FGF = fibroblast growth factor; ESR = erythrocyte sedimentation rate; PDGF = platelet-derived growth factor; CCLs = chemokine (C-C motif) ligands; MCPs = monocyte chemoattractant proteins; EGF = endothelial growth factor; IFN = interferon; iNOS = inducible nitric oxide synthase; eNOS = endothelial nitric oxide synthase; HIF-1 α = hypoxia-inducible factor 1 alpha; Ki-67 = Ki67; NF- κ B = nuclear factor kappa B; MPO = myeloperoxidase; TIMPs = tissue inhibitors of metalloproteinases; ROS = reactive oxygen species; p-ERK = phosphorylated Extracellular Signal-Regulated Kinase; IGF = Insulin-like growth factor).

| Repeated Chemical Biomarkers | Sources | | | Study Categories | | |
|------------------------------|---------|--------------------|---|------------------|-----------------|------------------------|
| | Freq. | % Included Sources | References | Freq. | % of Categories | Categories Included |
| ILs | 50 | 25% | (42, 45, 48, 54, 57, 75, 80, 87, 91, 101, 103, 105, 107, 108, 110, 111, 117, 121, 124, 130, 135, 137, 138, 153, 156, 158, 161, 167, 170, 173, 176, 177, 180, 183, 187, 191, 194, 196, 198, 205, 206, 209, 212, 213, 215, 216, 223, 226, 227, 236) | 7 | 54% | 1, 3, 4, 9, 10, 11, 12 |
| HbA1c | 48 | 24% | (46, 58, 59, 61, 63, 67, 69, 72-74, 81, 83, 84, 90, 92, 94, 102, 109, 123, 133, 134, 140, 143-147, 152, 157, 159, 160, 162, 169, 170, 172, 181, 189, 195, 197, 198, 200, 203, 207, 222, 224, 228, 230, 234) | 7 | 54% | 1, 2, 3, 4, 6, 7, 8 |
| VEGF | 39 | 19% | (42, 48, 51, 52, 54, 56, 59, 70, 75, 76, 99, 103, 108, 112-115, 119, 121, 124, 125, 143, 148, 153, 158, 161, 165, 167, 177, 184, 186, 190, 191, 193, 204, 205, 209, 223, 236) | 7 | 54% | 1, 3, 5, 9, 10, 11, 12 |
| CRP | 34 | 17% | (46, 47, 65, 69, 74, 78, 82-84, 90, 92, 94, 102, 106, 123, 129, 133, 134, 145, 150, 152, 157, 160, 164, 168, 170, 172, 185, 198, 199, 209, 220, 230, 235) | 6 | 46% | 1, 2, 6, 7, 8 |
| TNF | 34 | 17% | (42, 45, 54, 59, 71, 75, 76, 101, 103, 117, 121, 124, 135, 137, 153, 156, 158, 161, 167, 170, 173, 180, 191, 196, 198, 209, 212, 215, 216, 222, 223, 227, 232, 236) | 6 | 46% | 1, 3, 9, 10, 11, 12 |
| Albumin | 31 | 15% | (43, 44, 46, 58, 60, 63, 65, 77-79, 83, 84, 90, 102, 104, 106, 116, 133, 134, 157, 160, 161, 163, 172, 173, 179, 189, 198, 220, 234, 235) | 5 | 38% | 3, 6, 7, 8, 12 |
| TGF | 29 | 14% | (42, 51, 59, 70, 75, 76, 103, 113, 117, 121, 124, 132, 135, 137, 148, 158, 161, 165, 167, 170, 182, 183, 190, 191, 213, 215, 233, 236, 238) | 6 | 46% | 1, 3, 9, 10, 11, 12 |
| WBC | 27 | 13% | (44, 47, 59, 63, 77, 78, 82-84, 90, 94, 116, 123, 133, 134, 142, 152, 157, 159, 169, 172, 195, 220, 224, 230, 234, 235) | 6 | 46% | 2, 3, 4, 6, 7, 8 |
| CD31 | 27 | 13% | (51, 55, 66, 71, 80, 93, 96, 103, 105, 107, 114, 119, 148, 165, 174, 177, 187, 190, 191, 194, 206, 208, 209, 211, 218, 219, 233) | 3 | 23% | 9, 10, 12 |
| Hb | 26 | 13% | (46, 47, 58, 61, 63, 69, 72, 78, 83, 84, 90, 94, 106, 116, 120, 133, 134, 145, 160, 168, 172, 189, 195, 197, 198, 217) | 5 | 38% | 2, 3, 6, 7, 8 |
| α -SMA | 23 | 11% | (54, 55, 71, 87, 88, 103, 113, 117, 119, 136, 148, 153, 174, 177, 178, 180, 190-192, 213, 215, 216, 233) | 3 | 23% | 9, 10, 12 |
| MMPs | 22 | 11% | (41, 45, 54, 59, 101, 113, 115, 167, 177, 191, 193, 202, 203, 211, 215, 216, 223, 226, 227, 232, 236, 239) | 5 | 38% | 3, 9, 10, 11, 12 |
| Collagen | 21 | 10% | (41, 54, 55, 59, 71, 75, 88, 105, 108, 113, 117, 137, 153, 191, 212-214, 216, 233, 236, 241) | 6 | 46% | 1, 3, 9, 10, 11, 12 |
| Creatinine | 20 | 10% | (77, 78, 84, 94, 116, 133, 134, 144, 157, 159, 161-163, 170, 173, 198, 199, 228, 234, 235) | 6 | 46% | 1, 3, 4, 6, 8, 12 |
| Cholesterol | 16 | 8% | (67, 69, 72, 74, 81, 84, 90, 92, 109, 133, 134, 170, 172, 224, 230, 234) | 3 | 23% | 1, 3, 6 |
| FGF | 16 | 8% | (41, 42, 49, 51, 98, 105, 107, 125, 136, 139, 148, 156, 166, 184, 191, 215) | 5 | 38% | 9, 10, 11, 12, 13 |
| ESR | 14 | 7% | (47, 59, 84, 94, 123, 133, 134, 157, 164, 198, 199, 207, 230, 235) | 3 | 23% | 1, 3, 6 |
| CCLs/MCPs | 12 | 6% | (42, 45, 108, 135, 148, 161, 177, 196, 206, 209, 212, 215) | 3 | 23% | 10, 11, 12 |
| PDGF | 11 | 5% | (42, 56, 76, 124, 125, 137, 141, 143, 161, 186, 236) | 5 | 38% | 3, 9, 10, 11, 12 |
| Fasting Blood Sugar | 11 | 5% | (61, 63, 67, 74, 84, 100, 133, 134, 143, 171, 230) | 2 | 15% | 3, 6 |
| Neutrophils and Lymphocytes | 11 | 5% | (47, 61, 63, 90, 129, 157, 171, 172, 179, 200, 224) | 3 | 23% | 3, 6, 7 |
| EGF | 10 | 5% | (41, 42, 56, 139, 143, 151, 166, 193, 198, 238) | 4 | 31% | 3, 10, 11, 13 |
| Total Proteins | 10 | 5% | (54, 92, 94, 117, 133, 134, 137, 185, 198, 234) | 3 | 23% | 3, 6, 9 |
| Platelets | 9 | 4% | (44, 47, 69, 79, 84, 133, 134, 142, 200) | 3 | 23% | 3, 6, 7 |
| IFN | 9 | 4% | (41, 45, 48, 91, 161, 173, 183, 198, 227) | 4 | 31% | 3, 10, 11, 12 |
| iNOS and eNOS | 9 | 4% | (71, 124, 167, 180, 191, 194, 206, 209, 226) | 2 | 15% | 9, 10 |
| HIF-1 α | 7 | 3% | (48, 114, 119, 186, 191, 194, 236) | 3 | 23% | 3, 9, 10 |
| Bacteria | 7 | 3% | (61, 91, 115, 138, 201, 225, 227) | 2 | 15% | 3, 10 |
| Ki-67 | 7 | 3% | (29, 51, 165, 177, 191, 219, 231) | 2 | 15% | 9, 10 |
| NF- κ B | 6 | 3% | (48, 54, 117, 121, 167, 236) | 2 | 15% | 3, 9 |
| MPO | 6 | 3% | (121, 213, 216, 219, 227, 233) | 2 | 15% | 9, 10 |
| Zinc | 5 | 2% | (58, 104, 106, 133, 134) | 2 | 15% | 6, 8 |
| TIMPs | 5 | 2% | (45, 108, 115, 203, 236) | 2 | 15% | 3, 11 |
| CD68 | 5 | 2% | (51, 117, 148, 155, 233) | 2 | 15% | 9, 12 |
| ROS | 5 | 2% | (49, 118, 165, 202, 218) | 2 | 15% | 9, 10 |
| Hematocrit | 4 | 2% | (44, 142, 152, 195) | 2 | 15% | 2, 7 |
| ERK, p-ERK, and p-ERK1/2 | 4 | 2% | (29, 54, 113, 192) | 2 | 15% | 9, 10 |
| IGF | 4 | 2% | (48, 124, 177, 236) | 2 | 15% | 3, 10 |

Table 5: Measurement techniques reported in included sources used to quantify gene expression, serum expression, and/or wound tissue expression of the identified repeated chemical biomarkers (ELISA = enzyme-linked immunosorbent assay; qRT-PCR = quantitative real-time polymerase chain reaction; biomarker abbreviations are defined in the **Table 4** caption).

| Repeated Chemical Biomarkers | Biomarker Measurement Techniques | | | | | | | | | | |
|------------------------------|----------------------------------|---------------|--------------------|-----------|-------------------------|-----------|--------------|----------------|--------------------|-----------------------|---------------------------------------|
| | Gene Expression | | Serum Expression | | Wound Tissue Expression | | | | | | |
| | qRT-PCR | TaqMan Assays | Routine Blood Test | ELISA Kit | Multiplex Immunoassay | ELISA Kit | Western Blot | Immunostaining | Gelatin Zymography | Multiplex Immunoassay | Luminol-Based Bioluminescence Imaging |
| Albumin | | | ✓ | | | | | | | | |
| α-SMA | | | | | | | | ✓ | | | |
| CCLs/MCPs | ✓ | ✓ | | ✓ | | ✓ | | ✓ | | | |
| CD31 | | | | | | | | ✓ | | | |
| CD68 | | | | | | | | ✓ | | | |
| Cholesterol | | | ✓ | | | | | | | | |
| Collagen | ✓ | | | | | | | | | | |
| Creatinine | | | ✓ | | | | | | | | |
| CRP | | | ✓ | | | | | | | | |
| EGF | | | | | | ✓ | ✓ | ✓ | | | |
| ERK, p-ERK, and p-ERK1/2 | ✓ | | | | | | ✓ | ✓ | | | |
| ESR | | | ✓ | | | | | | | | |
| Fasting blood sugar | | | ✓ | | | | | | | | |
| FGF | ✓ | | | | | ✓ | | ✓ | | | |
| Hematocrit | | | ✓ | | | | | | | | |
| Hb | | | ✓ | | | | | | | | |
| HbA1c | | | ✓ | | | | | | | | |
| HIF-1α | ✓ | | | ✓ | | | ✓ | ✓ | | | |
| IFN | ✓ | | | ✓ | ✓ | | | | | ✓ | |
| IGF | ✓ | | | | | | | | | | |
| ILs | ✓ | | | ✓ | | ✓ | ✓ | | | | |
| iNOS and eNOS | | | | | | | ✓ | ✓ | | | |
| Ki-67 | | | | | | | | ✓ | | | |
| MMPs | ✓ | ✓ | | ✓ | | ✓ | ✓ | ✓ | ✓ | | |
| MPO | | | | | | ✓ | | ✓ | | | |
| Neutrophils and Lymphocytes | | | ✓ | | | | | | | | |
| NF-κB | ✓ | | | | | ✓ | ✓ | | | | |
| PDGF | ✓ | | | | | ✓ | | ✓ | | | |
| Platelets | | | ✓ | | | | | | | | |
| ROS | | | | | | | | ✓ | | | ✓ |
| TGF | ✓ | | | ✓ | | ✓ | | | | | |
| TIMPs | ✓ | ✓ | | | | ✓ | ✓ | | | | |
| TNF | ✓ | | | ✓ | | ✓ | | | | | |
| Total proteins | | | ✓ | | | | | | | | |
| VEGF | ✓ | | | ✓ | | ✓ | ✓ | ✓ | | | |
| WBC | | | ✓ | | | | | | | | |
| Zinc | | | ✓ | | | | | | | | |
| Totals | 15 | 3 | 14 | 8 | 1 | 12 | 9 | 16 | 1 | 1 | 1 |
| % of 37 Biomarkers | 41% | 8% | 3% | 22% | 3% | 32% | 24% | 43% | 3% | 3% | 3% |

3: MEASUREMENT TECHNIQUES OF THE REPEATED CHEMICAL BIOMARKERS

Gene expression was analyzed for 15 of the repeated chemical biomarkers using qRT-PCR (quantitative real-time polymerase chain reaction), including TaqMan assays (**Table 5** and **Table 6**). Immunostaining, to quantify biomarker expression in wound tissue samples, was similarly used for 15 of the 37 repeated biomarkers, such that qRT-PCR and immunostaining were the most frequently used quantification techniques. Interestingly, quantifying wound

tissue biomarker expression used the greatest array of measurement techniques, including ELISA (enzyme-linked immunosorbent assay) kits, Western Blot, immunostaining, gelatine zymography, and multiplex immunoassays.

The number of measurement techniques for each biomarker varied. MMPs, for example, were assessed using 7 techniques, whereas markers found in the blood such as HbA1c (glycated hemoglobin), Hb (hemoglobin), WBC (white blood cells), and platelets were analyzed using only one method, a routine blood test.

Table 6: Overview of the measurement techniques utilized in the included sources to quantify the chemical biomarkers referenced (**Table 4** (biomarkers); **Table 5** (corresponding quantification techniques); ELISA = enzyme-linked immunosorbent assay; MMP = matrix metalloproteinase; qRT-PCR = quantitative Real-Time Polymerase Chain Reaction; TaqDNA = Taq Deoxyribonucleic Acid Polymerase; miRNA = micro ribonucleic acid; BLI = bioluminescence imaging; NADPH = nicotinamide adenine dinucleotide phosphate; ROS = reactive oxygens species).

| Chemical Biomarker Measurement Technique | Brief Description of Principle |
|---|---|
| Gelatin Zymography | Method to detect proteolytic enzymes capable of degrading gelatin from biological sources such as the gelatinases MMP-2 and MMP-9 (244). |
| ELISA | Employs the catalytic properties of enzymes to detect and quantify immunologic reactions (245). It is a solid-phase test generating a color reaction and is therefore easy to interpret (246). |
| Multiplex Immunoassay | It utilizes traditional immunoassay methods working on the principle of exploiting binder molecules (antibodies, proteins, or peptides) to capture circulating proteins or antibodies (246). Unlike ELISA, multiplex immunoassays enable the simultaneous measurement of multiple analytes in a single biological sample (246). |
| TaqMan Assay | This is a specific form of qRT-PCR and one of the earliest methods introduced for real-time PCR monitoring (247). It exploits the 5' endonuclease activity of TaqDNA polymerase (an enzyme) to cleave an oligonucleotide probe during PCR, thereby generating a detectable signal (247). |
| Western Blot | Method to detect protein molecules among a mixture (248). The key steps include cell lysis (makes protein unfold into linear chains coated with a negative charge), gel electrophoresis (sorts proteins by size), blocking (prevents nonspecific reactions from occurring), incubating the sample with a primary antibody (binds specifically to the protein of interest), and finally incubating with a secondary antibody which binds to the primary and produces some signal (such as color or light) (248). |
| qRT-PCR | This is considered the gold standard for quantifying miRNAs with high sensitivity and specificity (249). It utilizes fluorescence generated during PCR to reflect the amount of DNA amplicons in a sample at a specific time (250). |
| Immunostaining | Requires incubating a tissue sample with antibodies specific to the protein of interest, which can then be visualized with a fluorescence (immunofluorescence) or chromogen (immunohistochemistry) which is bound to or binds to the antibody (251). |
| Luminol-Based Bioluminescence Imaging (BLI) | As demonstrated by Nguyen et al. (202), superoxide derived from NADPH oxidase can be detected through bioluminescence imaging by intraperitoneally injecting an animal with L-012. L-012 is a luminol-based chemiluminescent probe that emits light upon reacting with ROS (252). The intensity of the luminescent signal, measured in photons per second per centimeter squared, correlates with the amount of superoxide present, where a higher signal indicates greater superoxide levels, the most abundant ROS (253). |

Table 7: Classification of the repeated chemical biomarkers used in included sources as predictive, indicative, or diagnostic when considering their influence on the healing process and their behavior in the reviewed sources.

| Biomarker | Predictive | Indicative | Diagnostic | |
|--|--|------------|------------|--|
| Routine Blood Profile Biomarkers | Cholesterol (includes high and low-density lipoproteins and triglycerides) | ✓ | | |
| | Erythrocyte Sedimentation Rate (ESR) | ✓ | ✓ | |
| | Fasting Blood Sugar (or Fasting Plasma Glucose) | ✓ | | |
| | Glycated Hemoglobin (HbA1c) | ✓ | | |
| | Hematocrit (HCT) | ✓ | ✓ | |
| | Hemoglobin (Hb) | ✓ | | |
| | Neutrophils and Lymphocytes | ✓ | | |
| | Platelets | ✓ | | |
| | Total Proteins | ✓ | ✓ | |
| Growth Factors | White Blood Cell (WBC) Counts | ✓ | | |
| | Epidermal Growth Factor (EGF) | | ✓ | |
| | Fibroblast Growth Factor (FGF) | | ✓ | |
| | Insulin-Like Growth Factor (IGF) | | ✓ | |
| | Platelet-Derived Growth Factor (PDGF) | | ✓ | |
| | Transforming Growth Factor (TGF) | | ✓ | |
| | Tumor Necrosis Factor (TNF) | | ✓ | |
| Vascular Endothelial Growth Factor (VEGF) | | ✓ | | |
| Albumin | ✓ | | | |
| Alpha-Smooth Muscle Actin (α-SMA) | | ✓ | ✓ | |
| Bacteria (includes Colony-forming units, bacterial counts, and bacterial RNA assessment) | ✓ | | | |
| CC Chemokines (also known as Monocyte Chemoattractant [MCPs]) | | ✓ | | |
| Clusters of Differentiation (CD68 and CD31) | | | ✓ | |
| Collagen | | ✓ | ✓ | |
| C-Reactive Protein (CRP) | ✓ | ✓ | | |
| Creatinine | ✓ | | | |
| Endothelial and Inducible Nitric Oxide Synthase (eNOS and iNOS) | | ✓ | | |
| Extracellular Signal-Regulated Kinases (ERKs) | | ✓ | ✓ | |
| Hypoxia Inducible Factor-1 (HIF-1) | | ✓ | | |
| Interferon (IFN) | ✓ | ✓ | | |
| Interleukins (ILs) | ✓ | ✓ | ✓ | |
| Kiel-67 (Ki-67) | | ✓ | | |
| Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of Metalloproteinases (TIMPs) | | ✓ | ✓ | |
| Myeloperoxidase (MPO) | | ✓ | | |
| Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells (NF-κB) | | ✓ | | |
| Reactive Oxygen Species (ROS) | | ✓ | | |
| Zinc | ✓ | | | |

Bacteria were assessed somewhat differently, as presented in the following list, and are therefore excluded from **Table 5**:

- Biofilms were detected using the tissue culture plate method.
- Antimicrobial susceptibility testing was performed using the Kirby-Bauer disc diffusion method.
- Molecular characterization of biofilm-forming resistant isolates was done by PCR.

DISCUSSION

1: KEY FINDINGS

This scoping review identifies chemical biomarkers associated with the healing of tissues and structures in the residual limbs of adults with amputation. These biomarkers serve predictive, indicative, and diagnostic purposes, offering a foundation for improved prosthesis readiness and residuum health assessments.

Predictive biomarkers such as bacterial counts, nutritional markers (e.g., zinc, albumin), and routine blood markers (e.g., glycated hemoglobin [HbA1c], white blood cells [WBC], C-reactive protein [CRP]) indicate health status and help anticipate healing outcomes. For instance, elevated HbA1c is predictive of impaired healing due to hyperglycemia. Indicative biomarkers like growth factors, ILs, and reactive oxygen species (ROS) reflect critical healing processes, enabling monitoring of healing progression. Diagnostic biomarkers, such as alpha-smooth muscle actin (α -SMA), offer clear insights into wound healing at the cellular level.

Despite identifying 38 biomarkers in research, only routine blood markers are used clinically. Limited application stems from reliance on experimental methods (e.g., immunohistochemical staining) often restricted to animal studies. Bridging this gap requires advancements in measurement techniques that negate the need for wound tissue samples.

Population-specific factors (e.g., age, gender, comorbidities) and measurement differences (e.g., timing, location) influence healing and biomarker behavior. Thus, to improve healing assessment objectivity, a combination of biomarkers is required.

2: REPEATED CHEMICAL BIOMARKERS

2.1: Chemical Biomarkers

To classify a biomarker as predictive, indicative, or diagnostic (**Table 7**), its role in the healing process and observed behavior in the reviewed sources must be considered. For example, interleukins (ILs), a class of cytokines predominantly expressed by leukocytes, are

integral to inflammatory and immune responses²⁵⁴ and critical for wound healing. For instance, IL-2 receptors are present on macrophages, lymphocytes, keratinocytes, fibroblasts, vascular endothelial cells, and T-cells; cells that influence the entire healing process.²⁵⁵ Additionally, research on the treatment of diabetic foot ulcers (DFUs) with Therapeutic Magnetic Resonance (TMR[®]) devices revealed increased IL-10 expression and improved healing.⁷⁵ Similarly, elevated IL-1RL2 and IL-33 gene expression is linked to inflammation and bone remodeling, suggesting predictive potential for healing post-percutaneous osseointegrated prosthesis implantation.¹³⁰ Thus, ILs can be predictive, indicative, and diagnostic of healing.

Predictive biomarkers, such as bacterial counts, nutritional markers (like zinc and albumin), and routine blood profile markers like glycated hemoglobin (HbA1c), white blood cell counts (WBCs), and C-reactive protein (CRP), indicate an individual's health status, enabling the anticipation of healing outcomes. For example, bacterial counts reflect the wound microbiome and potential infection, which impairs healing.²⁵⁶ Similarly, HbA1c indicates glycemic control²⁴³ and predicts healing, as hyperglycemia inhibits keratinocyte migration and promotes oxidative stress through reactive oxygen species (ROS) production.²⁵⁷ Zinc is a marker of nutritional status,²⁵⁸ with deficiency negatively impacting healing,²⁵⁹ and supplementation accelerating it.²⁶⁰ Predictive biomarkers primarily identify comorbidities or conditions, such as infection or poor nutritional status, that contribute to impaired healing rather than diagnosing specific healing mechanisms. This makes them appropriate for pre-amputation risk assessments, given the high prevalence of comorbidities, such as diabetes, among individuals undergoing amputation. For example, the Scottish Physiotherapy Amputee Research Group (SPARG) reported in 2019 that 56% of lower limb amputees recorded had the etiology of diabetes.²⁶¹

Indicative biomarkers, including growth factors (**Table 7**), ILs, and signaling molecules like ROS and nuclear factor kappa-light-chain-enhancer of activated B cells (NF- κ B), reflect biological processes essential for healing (e.g., tissue remodeling and cellular proliferation), enabling monitoring and quantification of progress. For example, vascular endothelial growth factor (VEGF) promotes angiogenesis by influencing vascular endothelial cells, keratinocytes, and macrophages.²⁶² Supporting this, Kim et al.¹⁰³ demonstrated that increased VEGF levels correlated with near-complete epithelial coverage in a diabetic wound mouse model treated with Substance P, indicating healing.

The 6 identified diagnostic biomarkers (**Table 7**) provide insights into tissue structure and composition, enabling precise healing assessments. For example, alpha-smooth muscle actin (α -SMA), expressed temporarily by myofibroblasts during their differentiation from granulation tissue fibroblasts,²⁶³ serves as a marker of smooth muscle

differentiation and wound contraction,²⁶⁴ diagnosing healing progression during the epithelialization phase. By directly reflecting healing at a cellular level, diagnostic biomarkers offer the most objective insights into healing progression and hold high objective value for inclusion in a post-amputation healing assessment scale.

While numerous biomarkers show promise for enhancing post-amputation healing, their clinical application requires careful categorization and validation. Indicative biomarkers, such as growth factors, also diagnose specific molecular mechanisms, suggesting potential as diagnostic tools. For example, Ki-67, a marker of cellular proliferation,^{26,27} plays a diagnostic role by identifying fibroblast, endothelial cell, and keratinocyte proliferation (key processes in cutaneous wound healing).²⁸ However, further research in amputee-specific populations is needed to validate such biomarkers for clinical use, facilitating their transition from bench research to diagnostic applications.

Many identified biomarkers, including ILs and WBCs, are integral to immune and inflammatory responses. Elevated WBC counts (leukocytosis), for instance, are linked to higher risks of re-amputation, longer post-amputation healing times, and greater chance of amputation due to DFUs.^{44,84,235} However, leukocytosis may stem from factors unrelated to wound healing, such as infections elsewhere, medications, stress, or serious conditions like leukemia.²⁶⁵ To address this variability in biomarker causation, a broader array of biomarkers is needed to capture all phases of healing and account for patient-specific factors known to affect healing like stress,²⁶⁶ poor nutrition,²⁵⁹ renal disease,²⁶⁷ smoking,^{268,269} and alcohol use.²⁷⁰

The limitations of predictive biomarkers are evident in conflicting findings. To illustrate, Adams et al.⁴³ reported higher mortality rates after transmetatarsal amputation (TMA) in patients with preoperative albumin levels below 3.5 g/dL ($p < 0.05$). Similarly, Brookes et al.⁵⁸ observed significantly lower albumin levels in amputees compared to non-amputees ($p = 0.03$). However, Ahn et al.⁴⁴ found no significant correlation between serum albumin and TMA re-amputation rates ($p = 0.644$). Although the sources differ in participant populations and follow-up durations, the contrasting conclusions highlight the need for a biomarker profile rather than relying on a single predictive biomarker. This will enhance predictive accuracy whilst acknowledging a biomarker's limitations.

Future research must clarify the impact of quantification timing and location on biomarker levels during healing, to optimize their clinical application. For example, Anguiano-Hernandez et al.⁴⁸ demonstrated that NF- κ B expression and localization are indicative of healing progression. In DFU patients treated with hyperbaric oxygen therapy, NF- κ B expression decreased, and its localization shifted from nuclear to cytoplasmic in endothelial cells and fibroblasts,

correlating with complete healing.⁴⁸ These findings stress the importance of not only measuring biomarker levels but also assessing their localization to fully understand their role in the healing process.

A comprehensive biomarker profile that spans predictive, indicative, and diagnostic categories is essential to enhance the assessment and management of post-amputation healing. Such profiles would account for comorbidities, capture all healing stages, and improve clinical decision-making, particularly in early prosthetic rehabilitation.

2.2: Quantification Techniques

The method by which a biomarker is quantified dictates its applicability in research and clinical settings. Diagnostic markers like Ki-67, CD (clusters of differentiation), α -SMA, and ERKs (extracellular signal-regulated kinases) rely on techniques such as immunohistochemical staining, immunofluorescence, or RT-qPCR (Table 5), which require tissue samples, making them time-consuming, costly, and ethically challenging in human studies. Consequently, their use is largely confined to murine models emphasizing the need for advancements in quantification techniques. For example, ROS can be quantified via non-invasive in vivo chemiluminescence imaging,²⁰² validated in animal models²⁷¹ but untested clinically.

Conversely, biomarkers like CRP and routine blood markers, measurable through peripheral blood draws,²⁷² are more feasible for human studies and already employed in clinical settings.²⁷³ Unfortunately, such biomarkers are typically predictive or indicative, whereas markers like Ki-67 and α -SMA are diagnostic and thus hold greater clinical value.

Developing accessible, cost-effective, and ethically viable quantification techniques will facilitate the integration of chemical biomarkers into research and clinical practice, ultimately optimizing post-amputation healing and prosthetic rehabilitation outcomes.

3: OVERALL SEARCH RESULTS AND STUDY CHARACTERISTICS

Trends in study characteristics align with the findings from the Part 2 review;¹⁸ for full details, refer to Part 2. Diabetic wounds dominated the reviewed sources, reflecting the global diabetes burden,²⁷⁴ with DFUs being a major diabetic complication²⁷⁵ and a risk factor for amputation,^{276,277} reinforcing the importance of pre-amputation biomarker assessments to identify comorbidities predictive of non-healing like diabetes.⁸

Aging further complicates the healing process, with the median mean age of participants in Study Categories 1 to 8 ranging from 58.1 to 72.0 years. Non-healing wounds are often linked to vascular disease,²⁷⁸ venous insufficiency,²⁷⁹

areas of high unrelieved pressure,²⁸⁰ diabetes,²⁸¹ and disability;²⁸² conditions that are increasingly prevalent as the population ages.²⁸¹ Aging contributes to prolonged inflammation and increased ROS production,²⁸³ necessitating objective measures to monitor wound healing, particularly for older adults requiring prosthetic fitting.²⁶¹

Gender differences were evident, with male participants at higher risk for DFU development,²⁸⁴ poorer DFU healing,²⁸⁵ increased post-surgery infection rates,²⁸⁶ and higher in-hospital mortality rates after trauma.²⁸⁷ This highlights the need for gender-specific research²⁸⁸ and biomarkers unaffected by hormonal or gender-related factors.

Most included sources investigated wound healing in populations similar to individuals with amputation rather than residual limb healing specifically, highlighting the lack of standardized approaches and the need for a foundational database of biomarkers for residual limb recovery, particularly for lower limbs, which have unique health requirements due to weight-bearing during ambulation.

4: METHODOLOGICAL DISCUSSION

4.1: Methodological Strengths

This review's methodology aligns with [Part 1](#) and [Part 2](#); detailed discussions of methodological strengths, limitations, and ethical considerations can be found there.

This review broadly explored chemical biomarkers associated with post-amputation healing, serving as a foundation for future systematic reviews on specific biomarkers supported by high-quality evidence. A key strength is its focus on diagnostic, predictive, and indicative biomarkers with the potential to improve the prevention and treatment of non-healing surgical sites and to enhance post-amputation healing assessment, enabling timely prosthetic interventions.²⁸⁹

4.2: Methodological Limitations

Limitations include the unreliability of animal studies due to biological differences²⁹⁰ and the oversimplification of human biology in mathematical models,^{291,293} requiring cautious interpretation of biomarker behavior reported in these source types. While the review included wound types relevant to the residuum, future research should differentiate between the healing of secondary intention wounds (e.g., DFUs) and primary intention wounds (e.g., surgical sites). Additionally, prioritizing only repeatedly studied biomarkers risks oversimplification.

5: ETHICAL CONSIDERATIONS

Ethical rigor was prioritized over strict adherence to evidence hierarchies, such that only studies with clear ethical approval and informed consent from participants

aged 18 or older were included. Grey literature was reviewed to reduce bias,²⁹⁴ but none met the inclusion criteria due to methodological shortcomings and lack of ethical transparency.

CONCLUSION

This scoping review identified 38 repeated chemical biomarkers relevant to healing in the tissues and structures in residual limbs of adults with amputation, classified as predictive, indicative, or diagnostic based on their function and behavior in the 203 reviewed sources. Predictive biomarkers, such as blood markers (e.g., glycated hemoglobin [HbA1c], white blood cells [WBC]), assess health and healing potential, aiding pre-amputation risk assessments and identifying conditions impairing healing, like infection or poor nutrition. Indicative biomarkers, including growth factors and interleukins (ILs), reflect biological processes like cell proliferation and tissue remodeling, essential for post-amputation healing. For instance, vascular endothelial growth factor (VEGF) supports angiogenesis (blood vessel formation), a key healing component. Diagnostic biomarkers, such as alpha-smooth muscle actin (α -SMA), reveal tissue structure and healing progress at the cellular level.

While many biomarkers show potential for improving post-amputation healing, their clinical application requires careful validation in amputee populations. Biomarkers like WBCs play a key role in immune responses, but elevated WBC counts can be influenced by factors unrelated to wound healing, such as infections or stress. Using a biomarker array could better capture all healing stages and account for comorbidities, population differences, and lifestyle factors (e.g. infection, poor nutrition, smoking, alcohol use, gender, and age) known to affect healing. Understanding the impact of biomarker quantification, timing and location (e.g. wound fluid or serum) is crucial for clinical optimization.

Integrating diagnostic biomarkers into clinical practice is challenged by the invasive and complex nature of current measurement techniques. Most biomarkers, apart from routine blood markers like cholesterol and WBC counts (which are predictive of healing), remain confined to research due to reliance on techniques like immunohistochemistry requiring tissue samples, raising ethical and logistical barriers. Further research must develop accessible, non-invasive diagnostic tools. Bridging the gap between experimental research and clinical application is essential to standardize post-amputation healing assessments, reduce subjectivity, and ultimately enhance patient rehabilitation outcomes.

ACKNOWLEDGEMENTS

The author of this article would like to express appreciation to the Strathclyde Body Device Interface Mechanobiology Research

Group for their assistance in the discussion of the review's methodology.

DECLARATION OF CONFLICTING INTERESTS

The author has no conflicts of interest to declare.

AUTHORS' CONTRIBUTION

- **Hannelore Williams-Reid:** the primary author of the manuscript, undertook the scoping review and prepared the final manuscript as part of a 4-year PhD program.
- **Arjan Buis:** the primary PhD supervisor, assisted in developing the scoping review methodology and preparing the manuscript for publication.
- **Anton Johannesson:** the secondary PhD supervisor, assisted in developing the scoping review methodology and preparing the manuscript for publication.

All authors have read and approved the final version of the manuscript.

SOURCES OF SUPPORT

The PhD project under which this scoping review/manuscript falls is funded by the UKRI EPSRC as part of the Centre of Doctoral Training (CDT) in Prosthetics and Orthotics (P&O) (studentship 2755854 "Wound management and early prosthetic rehabilitation" within project EP/S02249X/1) and by Össur.

REFERENCES

- 1.Herman TF, Bordoni B. Wound Classification. Wound Classification [Internet]. StatPearls. 2024; [cited 2024, July 5]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK554456/>
- 2.Wallace HA BB, Zito PM. Wound Healing Phases [Internet]. StatPearls. 2023; [cited 2024, July 5]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK470443/>
- 3.Stroncek JD, Reichert WM. Overview of wound healing in different tissue types. In: Reichert WM, editor. *Indwelling neural implants: Strategies for contending with the in Vivo Environment*. Boca Raton (FL): CRC Press/Taylor & Francis; 2008. Chapter 1. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK3938/>
- 4.Guo S, Dipietro LA. Factors affecting wound healing. *J Dent Res*. 2010;89(3):219-29. DOI:10.1177/0022034509359125
- 5.Armstrong DG, Meyr AJ. Risk factors for impaired wound healing and wound complications. Wolters Kluwer; 2023; Available from: <https://www.uptodate.com/contents/risk-factors-for-impaired-wound-healing-and-wound-complications>
- 6.Kumar D, Singh S, Shantanu K, Goyal R, Kushwaha NS, Gupta AK, et al. Need of revision of lower limb amputations in a north Indian tertiary care centre. *J Clin Diagn Res*. 2015;9(12):Rc01-3. DOI:10.7860/jcdr/2015/16385.6886
- 7.Choo YJ, Kim DH, Chang MC. Amputation stump management: A narrative review. *World J Clin Cases*. 2022;10(13):3981-8. DOI:10.12998/wjcc.v10.i13.3981
- 8.Day JD, Dionne CP, James S, Wang H. Determinants of healing and readiness for prosthetic fitting after transtibial amputation:

Integrative literature review. *Prosthet Orthot Int*. 2023;47(1):43-53. DOI:10.1097/pxr.000000000000163

9.Geertzen JH, Martina JD, Rietman HS. Lower limb amputation. Part 2: Rehabilitation--a 10 year literature review. *Prosthet Orthot Int*. 2001;25(1):14-20. DOI:10.1080/03093640108726563

10. Miller TA, Paul R, Forthofer M, Wurdeman SR. Impact of time to receipt of prosthesis on total healthcare costs 12 months postamputation. *Am J Phys Med Rehabil*. 2020;99(11):1026-31. DOI:10.1097/phm.0000000000001473

11.Singh RK, Prasad G. Long-term mortality after lower-limb amputation. *Prosthet Orthot Int*. 2016;40(5):545-51. DOI:10.1177/0309364615596067

12.Optimising the timing for prosthetic fitting [Internet]. Bush & Co. 2024; [cited 2024, July 5]. Available from: <https://www.bushco.co.uk/news/optimal-time-for-fitting-a-prosthetic.html>

13.Turner S, Belsi A, McGregor AH. Issues faced by prosthetists and physiotherapists during lower-limb prosthetic rehabilitation: A thematic analysis. *Front Rehabil Sci*. 2021;2:795021. DOI:10.3389/fresc.2021.795021

14.Kwah LK, Webb MT, Goh L, Harvey LA. Rigid dressings versus soft dressings for transtibial amputations. *Cochrane Database Syst Rev*. 2019;6(6): Cd012427. DOI:10.1002/14651858.CD012427.pub2

15.Safari MR, Rowe P, McFadyen A, Buis A. Hands-off and hands-on casting consistency of amputee below knee sockets using magnetic resonance imaging. *ScientificWorldJournal*. 2013;2013:486146. DOI:10.1155/2013/486146

16.Focus Area: Biomarkers [Internet]. FDA (U.S. Food and Drug Administration). 2022; [cited 2024, July 5]. Available from: <https://www.fda.gov/science-research/focus-areas-regulatory-science-report/focus-area-biomarkers>

17.Williams-Reid H, Johannesson A, Buis A. Wound management, healing, and early prosthetic rehabilitation: part 1 - a scoping review of healing and non-healing definitions. *Can Prosthet Orthot J*. 2024;7(2). DOI:10.33137/cpoj.v7i2.43715

18.Williams-Reid H, Johannesson A, Buis A. Wound management, healing, and early prosthetic rehabilitation: part 2 - a scoping review of physical biomarkers. *Can Prosthet Orthot J*. 2024;7(2). DOI:10.33137/cpoj.v7i2.43716. DOI:10.33137/cpoj.v7i2.43716

19.Lin YH, Chen YC, Cheng KS, Yu PJ, Wang JL, Ko NY. Higher periwound temperature associated with wound healing of pressure ulcers detected by infrared thermography. *J Clin Med*. 2021;10(13). DOI:10.3390/jcm10132883

20.Kanazawa T, Kitamura A, Nakagami G, Goto T, Miyagaki T, Hayashi A, et al. Lower temperature at the wound edge detected by thermography predicts undermining development in pressure ulcers: A pilot study. *Int Wound J*. 2016;13(4):454-60. DOI:10.1111/iwj.12454

21.Nakagami G, Sanada H, Iizaka S, Kadono T, Higashino T, Koyanagi H, et al. Predicting delayed pressure ulcer healing using thermography: a prospective cohort study. *J Wound Care*. 2010;19(11):465-6, 8, 70 passim. DOI:10.12968/jowc.2010.19.11.79695

22. Menzel A, Samouda H, Dohet F, Loap S, Ellulu MS, Bohn T. Common and novel markers for measuring inflammation and oxidative stress ex vivo in research and clinical practice-which to use regarding disease outcomes? *Antioxidants (Basel)*. 2021;10(3). DOI:10.3390/antiox10030414
23. Gibson DJ, Schultz GS. Molecular wound assessments: Matrix metalloproteinases. *Adv Wound Care (New Rochelle)*. 2013;2(1):18-23. DOI:10.1089/wound.2011.0359
24. Utz ER, Elster EA, Tadaki DK, Gage F, Perdue PW, Forsberg JA, et al. Metalloproteinase expression is associated with traumatic wound failure. *J. Surg. Res.* 2010;159(2):633-9. DOI:10.1016/j.jss.2009.08.021
25. Kandhwal M, Behl T, Singh S, Sharma N, Arora S, Bhatia S, et al. Role of matrix metalloproteinase in wound healing. *Am J Transl Res.* 2022;14(7):4391-405
26. Sun X, Kaufman PD. Ki-67: More than a proliferation marker. *Chromosoma.* 2018;127(2):175-86. DOI:10.1007/s00412-018-0659-8
27. Betz P, Nerlich A, Wilske J, Tübel J, Penning R, Eisenmenger W. The time-dependent localization of Ki67 antigen-positive cells in human skin wounds. *Int J Legal Med.* 1993;106(1):35-40. DOI:10.1007/bf01225022
28. Liang X, Bhattacharya S, Bajaj G, Guha G, Wang Z, Jang HS, et al. Delayed cutaneous wound healing and aberrant expression of hair follicle stem cell markers in mice selectively lacking Ctip2 in epidermis. *PLoS One.* 2012;7(2):e29999. DOI:10.1371/journal.pone.0029999
29. Escuin-Ordinas H, Liu Y, Sun L, Hugo W, Dimatteo R, Huang RR, et al. Wound healing with topical BRAF inhibitor therapy in a diabetic model suggests tissue regenerative effects. *PLoS One.* 2021;16(6):e0252597. DOI:10.1371/journal.pone.0252597
30. Gajbhiye S, Wairkar S. Collagen fabricated delivery systems for wound healing: A new roadmap. *Biomater Adv.* 2022;142:213152. DOI:10.1016/j.bioadv.2022.213152
31. PRISMA for Scoping Reviews [Internet]. PRISMA. 2024; [cited 2024, July 5]. Available from: <https://www.prisma-statement.org/scoping>
32. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation. *Ann Intern Med.* 2018;169(7):467-73. DOI:10.7326/m18-0850
33. Peters MDJ, Marnie C, Tricco AC, Pollock D, Munn Z, Alexander L, et al. Updated methodological guidance for the conduct of scoping reviews. *JBI Evid Synth.* 2020;18(10):2119-26. DOI:10.11124/jbies-20-00167
34. Pollock D, Davies EL, Peters MDJ, Tricco AC, Alexander L, McInerney P, et al. Undertaking a scoping review: A practical guide for nursing and midwifery students, clinicians, researchers, and academics. *J Adv Nurs.* 2021;77(4):2102-13. DOI:10.1111/jan.14743
35. Pollock D, Peters MDJ, Khalil H, McInerney P, Alexander L, Tricco AC, et al. Recommendations for the extraction, analysis, and presentation of results in scoping reviews. *JBI Evid Synth.* 2023;21(3):520-32. DOI:10.11124/jbies-22-00123
36. Khalil H, Peters MD, Tricco AC, Pollock D, Alexander L, McInerney P, et al. Conducting high quality scoping reviews-challenges and solutions. *J Clin Epidemiol.* 2021;130:156-60. DOI:10.1016/j.jclinepi.2020.10.009
37. Bryda EC. The Mighty Mouse: the impact of rodents on advances in biomedical research. *Mo Med.* 2013;110(3):207-11
38. Leanne M. Kmet, Robert C. Lee, Cook LS. Standard quality assessment criteria for evaluating primary research papers from a variety of fields [Internet]. Alberta Heritage Foundation for Medical Research. 2014; [cited 2024, July 5]. Available from: https://www.ihe.ca/download/standard_quality_assessment_criteria_for_evaluating_primary_research_papers_from_a_variety_of_fields.pdf
39. JBI levels of evidence [Internet]. Joanna Briggs Institute. 2013; [cited 2024, July 5]. Available from: https://jbi.global/sites/default/files/2019-05/JBI-Levels-of-evidence_2014_0.pdf
40. Williams-Reid H, Buis A, Johannesson A, Lechler K. Wound management, healing, and early prosthetic rehabilitation: a scoping review of biomarkers. 2023. Abstract from The Future of prosthetics and Orthotics- 2nd CDT P&O conference, Glasgow, United Kingdom. Available from: <https://doi.org/10.15129/f5044ee8-5689-49c2-a67a-1cbe26af8a58>
41. Abedin-Do A, Zhang Z, Douville Y, Méthot M, Bernatchez J, Rouabhia M. Engineering diabetic human skin equivalent for in vitro and in vivo applications. *Front Bioeng Biotechnol.* 2022;10:989888. DOI:10.3389/fbioe.2022.989888
42. Abedin-Do A, Zhang Z, Douville Y, Méthot M, Rouabhia M. Effect of electrical stimulation on diabetic human skin fibroblast growth and the secretion of cytokines and growth factors involved in wound healing. *Biology (Basel)*. 2021;10(7). DOI:10.3390/biology10070641
43. Adams BE, Edlinger JP, Ritterman Weintraub ML, Pollard JD. Three-year morbidity and mortality rates after nontraumatic transmetatarsal amputation. *J Foot Ankle Surg.* 2018;57(5):967-71. DOI:10.1053/j.jfas.2018.03.047
44. Ahn J, Raspovic KM, Liu GT, Lavery LA, La Fontaine J, Nakonezny PA, et al. Renal function as a predictor of early transmetatarsal amputation failure. *Foot Ankle Spec.* 2019;12(5):439-51. DOI:10.1177/1938640018816371
45. Al-Rikabi AHA, Tobin DJ, Riches-Suman K, Thornton MJ. Dermal fibroblasts cultured from donors with type 2 diabetes mellitus retain an epigenetic memory associated with poor wound healing responses. *Sci Rep.* 2021;11(1):1474. DOI:10.1038/s41598-020-80072-z
46. AlJarrah Q, Allouh MZ, Husein A, Al-Jarrah H, Hallak A, Bakkar S, et al. Transmetatarsal amputations in patients with diabetes mellitus: A contemporary analysis from an academic tertiary referral centre in a developing community. *PLoS One.* 2022;17(11):e0277117. DOI:10.1371/journal.pone.0277117
47. Altay FA, Kuzi S, Altay M, Ateş İ, Gürbüz Y, Tütüncü EE, et al. Predicting diabetic foot ulcer infection using the neutrophil-to-lymphocyte ratio: a prospective study. *J Wound Care.* 2019;28(9):601-7. DOI:10.12968/jowc.2019.28.9.601

48. Anguiano-Hernandez YM, Contreras-Mendez L, de Los Angeles Hernandez-Cueto M, Muand Oz-Medina JE, Santillan-Verde MA, Barbosa-Cabrera RE, et al. Modification of HIF-1 α , NF- κ B, IGFBP-3, VEGF and adiponectin in diabetic foot ulcers treated with hyperbaric oxygen. *Undersea Hyperb Med.* 2019;46(1):35-44
49. Ariyanti AD, Zhang J, Marcelina O, Nugrahaningrum DA, Wang G, Kasim V, et al. Salidroside-pretreated mesenchymal stem cells enhance diabetic wound healing by promoting paracrine function and survival of mesenchymal stem cells under hyperglycemia. *Stem Cells Transl Med.* 2019;8(4):404-14. DOI:10.1002/sctm.18-0143
50. Bachar-Wikstrom E, Manchanda M, Bansal R, Karlsson M, Kelly-Pettersson P, Sköldenberg O, et al. Endoplasmic reticulum stress in human chronic wound healing: Rescue by 4-phenylbutyrate. *Int Wound J.* 2021;18(1):49-61. DOI:10.1111/iwj.13525
51. Bai H, Kyu-Cheol N, Wang Z, Cui Y, Liu H, Liu H, et al. Regulation of inflammatory microenvironment using a self-healing hydrogel loaded with BM-MSCs for advanced wound healing in rat diabetic foot ulcers. *J Tissue Eng.* 2020;11:2041731420947242. DOI:10.1177/2041731420947242
52. Barć P, Antkiewicz M, Śliwa B, Baczyńska D, Witkiewicz W, Skóra JP. Treatment of critical limb ischemia by pIRES/VEGF165/HGF administration. *Ann Vasc Surg.* 2019;60:346-54. DOI:10.1016/j.avsg.2019.03.013
53. Bayer A, Lammel J, Lippross S, Klüter T, Behrendt P, Tohidnezhad M, et al. Platelet-released growth factors induce psoriasis in keratinocytes: Implications for the cutaneous barrier. *Ann Anat.* 2017;213:25-32. DOI:10.1016/j.aanat.2017.04.002
54. Begum F, Manandhar S, Kumar G, Keni R, Sankhe R, Gurram PC, et al. Dehydrozingerone promotes healing of diabetic foot ulcers: A molecular insight. *J Cell Commun Signal.* 2023;17(3):673-88. DOI:10.1007/s12079-022-00703-0
55. Bian J, Bao L, Gao X, Wen X, Zhang Q, Huang J, et al. Bacteria-engineered porous sponge for hemostasis and vascularization. *J Nanobiotechnology.* 2022;20(1):47. DOI:10.1186/s12951-022-01254-7
56. Bibi S, Ahmad F, Alam MR, Ansar M, Yeou KS, Wahedi HM. Iapachol-induced upregulation of sirt1/sirt3 is linked with improved skin wound healing in alloxan-induced diabetic mice. *Iran J Pharm Res.* 2021;20(3):419-30. DOI:10.22037/ijpr.2021.112722.13914
57. Bramley JL, Worsley PR, Bostan LE, Bader DL, Dickinson AS. Establishing a measurement array to assess tissue tolerance during loading representative of prosthetic use. *Med Eng Phys.* 2020;78:39-47. DOI:10.1016/j.medengphy.2020.01.011
58. Brookes JDL, Jaya JS, Tran H, Vaska A, Werner-Gibbings K, D'Mello AC, et al. Broad-ranging nutritional deficiencies predict amputation in diabetic foot ulcers. *Int J Low Extrem Wounds.* 2020;19(1):27-33. DOI:10.1177/1534734619876779
59. Campitiello F, Mancone M, Cammarota M, D'Agostino A, Ricci G, Stellavato A, et al. Acellular dermal matrix used in diabetic foot ulcers: Clinical outcomes supported by biochemical and histological analyses. *Int J Mol Sci.* 2021;22(13). DOI:10.3390/ijms22137085
60. Chahrour MA, Kharroubi H, Al Tannir AH, Assi S, Habib JR, Hoballah JJ. Hypoalbuminemia is associated with mortality in patients undergoing lower extremity amputation. *Ann Vasc Surg.* 2021;77:138-45. DOI: 10.1016/j.avsg.2021.05.047
61. Chaudhary N, Huda F, Roshan R, Basu S, Rajput D, Singh SK. Lower limb amputation rates in patients with diabetes and an infected foot ulcer: A prospective observational study. *Wound Manag Prev.* 2021;67(7):22-30
62. Chen L, Ma W, Covassin N, Chen D, Zha P, Wang C, et al. Association of sleep-disordered breathing and wound healing in patients with diabetic foot ulcers. *J Clin Sleep Med.* 2021;17(5):909-16. DOI:10.5664/jcsm.9088
63. Cheng P, Dong Y, Hu Z, Huang S, Cao X, Wang P, et al. Biomarker prediction of postoperative healing of diabetic foot ulcers: A retrospective observational study of serum albumin. *Journal of Wound Ostomy & Continence Nursing.* 2021;48(4):339-44 DOI:10.1097/won.0000000000000780
64. Chowdary AR, Maerz T, Henn D, Hankenson KD, Pagani CA, Marini S, et al. Macrophage-mediated PDGF activation correlates with regenerative outcomes following musculoskeletal trauma. *Ann Surg.* 2023;278(2):e349-e59. DOI:10.1097/sla.0000000000005704
65. Das SK, Yuan YF, Li MQ. Predictors of delayed wound healing after successful isolated below-the-knee endovascular intervention in patients with ischemic foot ulcers. *J Vasc Surg.* 2018;67(4):1181-90. DOI:10.1016/j.jvs.2017.08.077
66. Ding Y, Cui L, Zhao Q, Zhang W, Sun H, Zheng L. Platelet-rich fibrin accelerates skin wound healing in diabetic mice. *Ann Plast Surg.* 2017;79(3):e15-e9. DOI:10.1097/sap.0000000000001091
67. Dinoto E, Ferlito F, La Marca MA, Tortomasi G, Urso F, Evola S, et al. The role of early revascularization and biomarkers in the management of diabetic foot ulcers: A single center experience. *Diagnostics (Basel).* 2022;12(2). DOI:10.3390/diagnostics12020538
68. Doulamis A, Doulamis N, Angeli A, Lazaris A, Luthman S, Jayapala M, et al. A non-invasive photonics-based device for monitoring of diabetic foot ulcers: Architectural/sensorial components & technical specifications. *Inventions.* 2021;6(2):27
69. Dutra LMA, Melo MC, Moura MC, Leme LAP, De Carvalho MR, Mascarenhas AN, et al. Prognosis of the outcome of severe diabetic foot ulcers with multidisciplinary care. *J Multidiscip Healthc.* 2019;12:349-59. DOI:10.2147/jmdh.S194969
70. El-Gizawy SA, Nouh A, Saber S, Kira AY. Deferoxamine-loaded transfersomes accelerates healing of pressure ulcers in streptozotocin-induced diabetic rats. *J Drug Deliv Sci Technol.* 2020;58:101732. DOI:10.1016/j.jddst.2020.101732
71. Elliott CG, Wang J, Walker JT, Michelsons S, Dunmore-Buyze J, Drangova M, et al. Periostin and CCN2 scaffolds promote the wound healing response in the skin of diabetic mice. *Tissue Eng Part A.* 2019;25(17-18):1326-39. DOI:10.1089/ten.TEA.2018.0268
72. Ezeani IU, Ugwu ET, Adeleye FO, Gezawa ID, Okpe IO, Enamino MI. Determinants of wound healing in patients hospitalized for diabetic foot ulcer: results from the MEDFUN study. *Endocr Regul.* 2020;54(3):207-16. DOI:10.2478/enr-2020-0023
73. Farooque U, Lohano AK, Hussain Rind S, Rind MS, Sr., Karimi S, Jaan A, et al. Correlation of hemoglobin A1C with wagner

- classification in patients with diabetic foot. *Cureus*. 2020;12(7):e9199. DOI:10.7759/cureus.9199
- 74.Feldbrin Z, Omelchenko E, Lipkin A, Shargorodsky M. Osteopontin levels in plasma, muscles, and bone in patient with non-healing diabetic foot ulcers: A new player in wound healing process? *J Diabetes Complications*. 2018;32(8):795-8. DOI:10.1016/j.jdiacomp.2018.05.009
- 75.Ferroni L, Gardin C, De Pieri A, Sambataro M, Segnanfreddo E, Goretti C, et al. Treatment of diabetic foot ulcers with Therapeutic Magnetic Resonance (TMR[®]) improves the quality of granulation tissue. *Eur J Histochem*. 2017;61(3):2800. DOI:10.4081/ejh.2017.2800
- 76.Friedman A, Siewe N. Mathematical model of chronic dermal wounds in diabetes and obesity. *Bull Math Biol*. 2020;82(10):137. DOI:10.1007/s11538-020-00815-x
- 77.Furuyama T, Onohara T, Yamashita S, Yoshiga R, Yoshiya K, Inoue K, et al. Prognostic factors of ulcer healing and amputation-free survival in patients with critical limb ischemia. *Vascular*. 2018;26(6):626-33. DOI:10.1177/1708538118786864
- 78.Furuyama T, Yamashita S, Yoshiya K, Kurose S, Yoshino S, Nakayama K, et al. The controlling nutritional status score is significantly associated with complete ulcer healing in patients with critical limb ischemia. *Ann Vasc Surg*. 2020;66:510-7. DOI:10.1016/j.avsg.2019.12.031
- 79.Gao C, Yang L, Ju J, Gao Y, Zhang K, Wu M, et al. Risk and prognostic factors of replantation failure in patients with severe traumatic major limb mutilation. *Eur J Trauma Emerg Surg*. 2022;48(4):3203-10. DOI:10.1007/s00068-021-01876-w
- 80.Gao R, Zhou P, Li Y, Li Q. High glucose-induced IL-7/IL-7R upregulation of dermal fibroblasts inhibits angiogenesis in a paracrine way in delayed diabetic wound healing. *J Cell Commun Signal*. 2023;17(3):1023-38. DOI:10.1007/s12079-023-00754-x
- 81.Gazzaruso C, Gallotti P, Pujia A, Montalcini T, Giustina A, Coppola A. Predictors of healing, ulcer recurrence and persistence, amputation and mortality in type 2 diabetic patients with diabetic foot: a 10-year retrospective cohort study. *Endocrine*. 2021;71(1):59-68. DOI:10.1007/s12020-020-02431-0
- 82.Giesen LJ, van den Boom AL, van Rossem CC, den Hoed PT, Wijnhoven BP. Retrospective multicenter study on risk factors for surgical site infections after appendectomy for acute appendicitis. *Dig Surg*. 2017;34(2):103-7. DOI:10.1159/000447647
- 83.Gülcü A, Etili M, Karahan O, Aslan A. Analysis of routine blood markers for predicting amputation/re-amputation risk in diabetic foot. *Int Wound J*. 2020;17(6):1996-2004. DOI:10.1111/iwj.13491
- 84.Guo Z, Yue C, Qian Q, He H, Mo Z. Factors associated with lower-extremity amputation in patients with diabetic foot ulcers in a Chinese tertiary care hospital. *Int Wound J*. 2019;16(6):1304-13. DOI:10.1111/iwj.13190
- 85.Hansen RL, Langdahl BL, Jørgensen PH, Petersen KK, Søballe K, Stilling M. Changes in periprosthetic bone mineral density and bone turnover markers after osseointegrated implant surgery: A cohort study of 20 transfemoral amputees with 30-month follow-up. *Prosthet Orthot Int*. 2019;43(5):508-18. DOI:10.1177/0309364619866599
- 86.Hata Y, Iida O, Okamoto S, Ishihara T, Nanto K, Tsujumura T, et al. Additional risk stratification using local and systemic factors for patients with critical limb ischaemia undergoing endovascular therapy in the Wi-Fi era. *Eur J Vasc Endovasc Surg*. 2019;58(4):548-55. DOI:10.1016/j.ejvs.2019.06.005
- 87.He FL, Qiu S, Zou JL, Gu FB, Yao Z, Tu ZH, et al. Covering the proximal nerve stump with chondroitin sulfate proteoglycans prevents traumatic painful neuroma formation by blocking axon regeneration after neurotomy in Sprague Dawley rats. *J Neurosurg*. 2021;134(5):1599-609. DOI:10.3171/2020.3.Jns193202
- 88.He S, Walimbe T, Chen H, Gao K, Kumar P, Wei Y, et al. Bioactive extracellular matrix scaffolds engineered with proangiogenic proteoglycan mimetics and loaded with endothelial progenitor cells promote neovascularization and diabetic wound healing. *Bioact Mater*. 2022;10:460-73. DOI:10.1016/j.bioactmat.2021.08.017
- 89.Hohendorff J, Drozd A, Borys S, Ludwig-Slomczynska AH, Kiec-Wilk B, Stepien EL, et al. Effects of negative pressure wound therapy on levels of angiopoietin-2 and other selected circulating signaling molecules in patients with diabetic foot ulcer. *J Diabetes Res*. 2019;2019:1756798. DOI:10.1155/2019/1756798
- 90.Hung SY, Tsai JS, Yeh JT, Chen KH, Lin CN, Yang HM, et al. Amino acids and wound healing in people with limb-threatening diabetic foot ulcers. *J Diabetes Complications*. 2019;33(10):107403. DOI:10.1016/j.jdiacomp.2019.06.008
- 91.Huon JF, Gaborit B, Caillon J, Boutoille D, Navas D. A murine model of Staphylococcus aureus infected chronic diabetic wound: A new tool to develop alternative therapeutics. *Wound Repair Regen*. 2020;28(3):400-8. DOI:10.1111/wrr.12802
- 92.Husakova J, Bem R, Fejfarova V, Jirkovska A, Woskova V, Jarosikova R, et al. Factors influencing the risk of major amputation in patients with diabetic foot ulcers treated by autologous cell therapy. *J Diabetes Res*. 2022;2022:3954740. DOI:10.1155/2022/3954740
- 93.Icli B, Wu W, Ozdemir D, Li H, Haemmig S, Liu X, et al. MicroRNA-135a-3p regulates angiogenesis and tissue repair by targeting p38 signaling in endothelial cells. *Faseb j*. 2019;33(4):5599-614. DOI:10.1096/fj.201802063RR
- 94.Jeon BJ, Choi HJ, Kang JS, Tak MS, Park ES. Comparison of five systems of classification of diabetic foot ulcers and predictive factors for amputation. *Int Wound J*. 2017;14(3):537-45. DOI:10.1111/iwj.12642
- 95.Jere SW, Houreld NN, Abrahamse H. Photobiomodulation activates the PI3K/AKT pathway in diabetic fibroblast cells in vitro. *J Photochem Photobiol B*. 2022;237:112590. DOI:10.1016/j.jphotobiol.2022.112590
- 96.Ji X, Jin P, Yu P, Wang P. Autophagy ameliorates Pseudomonas aeruginosa-infected diabetic wounds by regulating the toll-like receptor 4/myeloid differentiation factor 88 pathway. *Wound Repair Regen*. 2023;31(3):305-20. DOI:10.1111/wrr.13074
- 97.Junaidi F, Muradi A, Pratama D, Suhartono R, Kekalih A. Effectiveness of doppler ultrasonography as a predictor of wound healing after below-knee amputation for peripheral arterial disease. *Chirurgia (Bucur)*. 2020;115(5):618-25. DOI:10.21614/chirurgia.115.5.618

98. Kasowanjete P, Abrahamse H, Houreld NN. Photobiomodulation at 660 nm stimulates *in vitro* diabetic wound healing via the Ras/MAPK pathway. *Cells*. 2023;12(7). DOI:10.3390/cells12071080
99. Katagiri T, Kondo K, Shibata R, Hayashida R, Shintani S, Yamaguchi S, et al. Therapeutic angiogenesis using autologous adipose-derived regenerative cells in patients with critical limb ischaemia in Japan: A clinical pilot study. *Sci Rep*. 2020;10(1):16045. DOI:10.1038/s41598-020-73096-y
100. Kee KK, Nair HKR, Yuen NP. Risk factor analysis on the healing time and infection rate of diabetic foot ulcers in a referral wound care clinic. *J Wound Care*. 2019;28(Sup1):S4-s13. DOI:10.12968/jowc.2019.28.Sup1.S4
101. Kim BE, Goleva E, Hall CF, Park SH, Lee UH, Brauweiler AM, et al. Skin wound healing is accelerated by a lipid mixture representing major lipid components of *chamaecyparis obtusa* plant extract. *J Invest Dermatol*. 2018;138(5):1176-86. DOI:10.1016/j.jid.2017.11.039
102. Kim KG, Mishu M, Zolper EG, Bhardwaj P, Rogers A, Dekker PK, et al. Nutritional markers for predicting lower extremity free tissue transfer outcomes in the chronic wound population. *Microsurgery*. 2023;43(1):51-6. DOI:10.1002/micr.30794
103. Kim S, Piao J, Hwang DY, Park JS, Son Y, Hong HS. Substance P accelerates wound repair by promoting neovascularization and preventing inflammation in an ischemia mouse model. *Life Sci*. 2019;225:98-106. DOI:10.1016/j.lfs.2019.04.015
104. Kodama A, Komori K, Koyama A, Sato T, Ikeda S, Tsuruoka T, et al. Impact of serum zinc level and oral zinc supplementation on clinical outcomes in patients undergoing infrainguinal bypass for chronic limb-threatening ischemia. *Circ J*. 2022;86(6):995-1006. DOI:10.1253/circj.CJ-21-0832
105. Kolumam G, Wu X, Lee WP, Hackney JA, Zavala-Solorio J, Gandham V, et al. IL-22R ligands IL-20, IL-22, and IL-24 promote wound healing in diabetic db/db Mice. *PLoS One*. 2017;12(1):e0170639 DOI:10.1371/journal.pone.0170639
106. Koyama A, Kodama A, Tsuruoka T, Fujii T, Sugimoto M, Banno H, et al. Zinc deficiency and clinical outcome after infrainguinal bypass grafting for critical limb ischemia. *Circ Rep*. 2020;2(3):167-73. DOI:10.1253/circrep.CR-20-0003
107. Kurkipuro J, Mierau I, Wirth T, Samaranayake H, Smith W, Kärkkäinen HR, et al. Four in one-combination therapy using live *Lactococcus lactis* expressing three therapeutic proteins for the treatment of chronic non-healing wounds. *PLoS One*. 2022;17(2):e0264775. DOI:10.1371/journal.pone.0264775
108. Laiva AL, O'Brien FJ, Keogh MB. SDF-1 α Gene-activated collagen scaffold restores pro-angiogenic wound healing features in human diabetic adipose-derived stem cells. *Biomedicines*. 2021;9(2). DOI:10.3390/biomedicines9020160
109. Lee JV, Engel C, Tay S, DeSilva G, Desai K, Cashin J, et al. Impact of N-acetyl-cysteine on ischemic stumps following major lower extremity amputation: a pilot randomized clinical trial. *Ann Surg*. 2022;276(5):e302-e10. DOI:10.1097/sla.0000000000005389
110. Lee Y-H, Lin S-J. Chitosan/PVA Hetero-composite hydrogel containing antimicrobials, perfluorocarbon nanoemulsions, and growth factor-loaded nanoparticles as a multifunctional dressing for diabetic wound healing: synthesis, characterization, and *in vitro/in vivo* evaluation. *Pharmaceutics*. 2022;14(3):537
111. Lee YH, Hong YL, Wu TL. Novel silver and nanoparticle-encapsulated growth factor co-loaded chitosan composite hydrogel with sustained antimicrobial and promoted biological properties for diabetic wound healing. *Mater Sci Eng C Mater Biol Appl*. 2021;118:111385. DOI:10.1016/j.msec.2020.111385
112. Leu JG, Chiang MH, Chen CY, Lin JT, Chen HM, Chen YL, et al. Adenine accelerated the diabetic wound healing by PPAR delta and angiogenic regulation. *Eur J Pharmacol*. 2018;818:569-77. DOI:10.1016/j.ejphar.2017.11.027
113. Li B, Zhou Y, Chen J, Wang T, Li Z, Fu Y, et al. Long non-coding RNA H19 contributes to wound healing of diabetic foot ulcer. *J Mol Endocrinol*. 2020. DOI:10.1530/jme-19-0242
114. Li G, Li D, Wu C, Li S, Chen F, Li P, et al. Homocysteine-targeting compounds as a new treatment strategy for diabetic wounds via inhibition of the histone methyltransferase SET7/9. *Exp Mol Med*. 2022;54(7):988-98. DOI:10.1038/s12276-022-00804-1
115. Li G, Zou X, Zhu Y, Zhang J, Zhou L, Wang D, et al. Expression and influence of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 and vascular endothelial growth factor in diabetic foot ulcers. *Int J Low Extrem Wounds*. 2017;16(1):6-13. DOI:10.1177/1534734617696728
116. Li J, Arora S, Ikeoka K, Smith J, Dash S, Kimura S, et al. The utility of geriatric nutritional risk index to predict outcomes in chronic limb-threatening ischemia. *Catheter Cardiovasc Interv*. 2022;99(1):121-33. DOI:10.1002/ccd.29949
117. Li J, Chou H, Li L, Li H, Cui Z. Wound healing activity of neferine in experimental diabetic rats through the inhibition of inflammatory cytokines and nrf-2 pathway. *Artif Cells Nanomed Biotechnol*. 2020;48(1):96-106. DOI:10.1080/21691401.2019.1699814
118. Li M, Li X, Gao Y, Yang Y, Yi C, Huang W, et al. Composite nanofibrous dressing loaded with Prussian blue and heparin for anti-inflammation therapy and diabetic wound healing. *Int J Biol Macromol*. 2023;242(Pt 3):125144. DOI:10.1016/j.ijbiomac.2023.125144
119. Li S, Wang X, Chen J, Guo J, Yuan M, Wan G, et al. Calcium ion cross-linked sodium alginate hydrogels containing deferoxamine and copper nanoparticles for diabetic wound healing. *Int J Biol Macromol*. 2022;202:657-70. DOI:10.1016/j.ijbiomac.2022.01.080
120. Lin BS, Chang CC, Tseng YH, Li JR, Peng YS, Huang YK. Using wireless near-infrared spectroscopy to predict wound prognosis in diabetic foot ulcers. *Adv Skin Wound Care*. 2020;33(1):1-12. DOI:10.1097/01.ASW.0000613552.50065.d5
121. Liu Y, Wang F, Chen B. Anti-Inflammatory and antioxidant effects of chrysin mitigates diabetic foot ulcers. *Int J Pharmacol*. 2023;19(1):122-30. DOI:10.3923/ijp.2023.122.130
122. Liu Y, Zhang X, Yang L, Zhou S, Li Y, Shen Y, et al. Proteomics and transcriptomics explore the effect of mixture of herbal extract on diabetic wound healing process. *Phytomedicine*. 2023;116:154892. DOI:10.1016/j.phymed.2023.154892

123. MacDonald A, Brodell JD, Jr., Daiss JL, Schwarz EM, Oh I. Evidence of differential microbiomes in healing versus non-healing diabetic foot ulcers prior to and following foot salvage therapy. *J Orthop Res.* 2019;37(7):1596-603. DOI:10.1002/jor.24279
124. Manso G, Elias-Oliveira J, Guimarães JB, Pereira Í S, Rodrigues VF, Burger B, et al. Xenogeneic mesenchymal stem cell biocurative improves skin wounds healing in diabetic mice by increasing mast cells and the regenerative profile. *Regen Ther.* 2023;22:79-89. DOI:10.1016/j.reth.2022.12.006
125. McLaughlin PJ, Cain JD, Titunick MB, Sassani JW, Zagon IS. Topical naltrexone is a safe and effective alternative to standard treatment of diabetic wounds. *Adv Wound Care (New Rochelle).* 2017;6(9):279-88. DOI:10.1089/wound.2016.0725
126. Mehrvar S, Rymut KT, Foomani FH, Mostaghimi S, Eells JT, Ranji M, et al. Fluorescence imaging of mitochondrial redox state to assess diabetic wounds. *IEEE J Transl Eng Health Med.* 2019;7:1800809. DOI:10.1109/jtehm.2019.2945323
127. Mendoza-Marí Y, García-Ojalvo A, Fernández-Mayola M, Rodríguez-Rodríguez N, Martínez-Jimenez I, Berlanga-Acosta J. Epidermal growth factor effect on lipopolysaccharide-induced inflammation in fibroblasts derived from diabetic foot ulcer. *Scars Burn Heal.* 2022;8:20595131211067380. DOI:10.1177/20595131211067380
128. Metcalf DG, Haalboom M, Bowler PG, Gamerith C, Sigl E, Heinze A, et al. Elevated wound fluid pH correlates with increased risk of wound infection. *Wound Med.* 2019;26(1):100166. DOI:10.1016/j.wndm.2019.100166
129. Metineren H, Dülgeroğlu TC. Comparison of the neutrophil/lymphocyte ratio and c-reactive protein levels in patients with amputation for diabetic foot ulcers. *Int J Low Extrem Wounds.* 2017;16(1):23-8. DOI:10.1177/1534734617696729
130. Miller A, Jeyapalina S, Agarwal J, Mansel M, Beck JP. A preliminary, observational study using whole-blood RNA sequencing reveals differential expression of inflammatory and bone markers post-implantation of percutaneous osseointegrated prostheses. *PLoS One.* 2022;17(5):e0268977. DOI:10.1371/journal.pone.0268977
131. Modaghegh MHS, Saberianpour S, Amoueian S, Shahri JJ, Rahimi H. The effect of redox signaling on extracellular matrix changes in diabetic wounds leading to amputation. *Biochem Biophys Rep.* 2021;26:101025. DOI:10.1016/j.bbrep.2021.101025
132. Mokoena DR, Houeild NN, Dhilip Kumar SS, Abrahamse H. Photobiomodulation at 660 nm stimulates fibroblast differentiation. *Lasers Surg Med.* 2020;52(7):671-81. DOI:10.1002/lsm.23204
133. Moon KC, Kim KB, Han SK, Jeong SH, Dhong ES. Risk factors for major amputation on hindfoot ulcers in hospitalized diabetic patients. *Adv Wound Care (New Rochelle).* 2019;8(5):177-85. DOI:10.1089/wound.2018.0814
134. Moon KC, Kim SB, Han SK, Jeong SH, Dhong ES. Risk factors for major amputation in hospitalized diabetic patients with forefoot ulcers. *Diabetes Res Clin Pract.* 2019;158:107905. DOI:10.1016/j.diabres.2019.107905
135. Morey M, O'Gaora P, Pandit A, Hélarý C. Hyperglycemia acts in synergy with hypoxia to maintain the pro-inflammatory phenotype of macrophages. *PLoS One.* 2019;14(8):e0220577. DOI:10.1371/journal.pone.0220577
136. Mutlu HS, Erdoğan A, Tapul L. Autologously transplanted dermal fibroblasts improved diabetic wound in rat model. *Acta Histochemica.* 2020;122(5):151552. DOI:10.1016/j.acthis.2020.151552
137. Nasrullah MZ. Caffeic acid phenethyl ester loaded PEG-PLGA nanoparticles enhance wound healing in diabetic rats. *Antioxidants (Basel).* 2022;12(1). DOI:10.3390/antiox12010060
138. Neama NA, Darweesh M, Al-Obiadi AB. Prevalence and antibiotic susceptibility pattern in diabetic foot ulcer infection with *Ev Alua Tion* The Role Of biomarker Il-12 in disease. *Biochem Cell Arch.* 2018;18:2321-8
139. Nensat C, Songjang W, Tohtong R, Suthiphongchai T, Phimsen S, Rattanasinganchan P, et al. Porcine placenta extract improves high-glucose-induced angiogenesis impairment. *BMC Complement Med Ther.* 2021;21(1):66. DOI:10.1186/s12906-021-03243-z
140. Newhall KA, Bekelis K, Suckow BD, Gottlieb DJ, Farber AE, Goodney PP, et al. The relationship of regional hemoglobin A1c testing and amputation rate among patients with diabetes. *Vascular.* 2017;25(2):142-8. DOI:10.1177/1708538116650099
141. Nishikai-Yan Shen T, Kado M, Hagiwara H, Fujimura S, Mizuno H, Tanaka R. MMP9 secreted from mononuclear cell quality and quantity culture mediates STAT3 phosphorylation and fibroblast migration in wounds. *Regen Ther.* 2021;18:464-71. DOI:10.1016/j.reth.2021.10.003
142. Norvell DC, Czerniecki JM. Risks and risk factors for ipsilateral re-amputation in the first year following first major unilateral dysvascular amputation. *Eur J Vasc Endovasc Surg.* 2020;60(4):614-21. DOI:10.1016/j.ejvs.2020.06.026
143. Ou S, Xu C, Yang Y, Chen Y, Li W, Lu H, et al. Transverse tibial bone transport enhances distraction osteogenesis and vascularization in the treatment of diabetic foot. *Orthop Surg.* 2022;14(9):2170-9. DOI:10.1111/os.13416
144. Rajagopalan C, Viswanathan V, Rajsekar S, Selvaraj B, Daniel L. Diabetic foot ulcers—comparison of performance of ankle-brachial index and transcutaneous partial oxygen pressure in predicting outcome. *Int J Diabetes Dev Ctries.* 2018;38(2):179-84. DOI:10.1007/s13410-017-0580-3
145. Rațiu IA, Rațiu CA, Miclăuș V, Boșca AB, Turan Kazancıoğlu R, Constantin AM, et al. The pioneer use of a modified PRGF-Endoret® technique for wound healing in a hemodialyzed diabetic patient in a terminal stage of renal disease. *Rom J Morphol Embryol.* 2021;62(2):465-73. DOI:10.47162/rjme.62.2.12
146. Razjouyan J, Grewal GS, Talal TK, Armstrong DG, Mills JL, Najafi B. Does physiological stress slow down wound healing in patients with diabetes? *J Diabetes Sci Technol.* 2017;11(4):685-92. DOI:10.1177/1932296817705397
147. Reiner MM, Khoury WE, Canales MB, Chmielewski RA, Patel K, Razzante MC, et al. Procalcitonin as a biomarker for predicting amputation level in lower extremity infections. *J Foot Ankle Surg.* 2017;56(3):484-91. DOI:10.1053/j.jfas.2017.01.014
148. Ridiandries A, Bursill C, Tan J. Broad-spectrum inhibition of the cc-chemokine class improves wound healing and wound

- angiogenesis. *Int J Mol Sci.* 2017;18(1). DOI:10.3390/ijms18010155
- 149.Salaun P, Desormais I, Lapébie FX, Rivière AB, Aboynans V, Lacroix P, et al. Comparison of ankle pressure, systolic toe pressure, and transcutaneous oxygen pressure to predict major amputation after 1 year in the COPART Cohort. *Angiology.* 2019;70(3):229-36. DOI:10.1177/0003319718793566
- 150.Sapienza P, Mingoli A, Borrelli V, Brachini G, Biacchi D, Sterpetti AV, et al. Inflammatory biomarkers, vascular procedures of lower limbs, and wound healing. *Int Wound J.* 2019;16(3):716-23. DOI:10.1111/iwj.13086
- 151.Sawaya AP, Jozic I, Stone RC, Pastar I, Egger AN, Stojadinovic O, et al. Mevastatin promotes healing by targeting caveolin-1 to restore EGFR signaling. *JCI Insight.* 2019;4(23). DOI:10.1172/jci.insight.129320
- 152.Seçkin MF, Özcan Ç, Çamur S, Polat Ö, Batar S. Predictive factors and amputation level for reamputation in patients with diabetic foot: A retrospective case-control study. *J Foot Ankle Surg.* 2022;61(1):43-7. DOI:10.1053/j.jfas.2021.06.006
- 153.Senturk B, Demircan BM, Ozkan AD, Tohumeken S, Delibasi T, Guler MO, et al. Diabetic wound regeneration using heparin-mimetic peptide amphiphile gel in db/db mice. *Biomater Sci.* 2017;5(7):1293-303. DOI:10.1039/c7bm00251c
- 154.Sharma GR, Kumar V, Kanojia RK, Vaiphei K, Kansal R. Fast and slow myosin as markers of muscle regeneration in mangled extremities: a pilot study. *Eur J Orthop Surg Traumatol.* 2019;29(7):1539-47. DOI:10.1007/s00590-019-02448-w
- 155.Shen YY, Zhang RR, Liu QY, Li SY, Yi S. Robust temporal changes of cellular senescence and proliferation after sciatic nerve injury. *Neural Regen Res.* 2022;17(7):1588-95. DOI:10.4103/1673-5374.330619
- 156.Shetty S, Pavan G, Shetty A, Kumari S, Shetty P, Patil P. Molecular signatures in diabetic foot ulcer by integrated gene expression profiling via bioinformatics analysis. *Biomedicine.* 2022;42:713-9. DOI:10.51248/v42i4.1798
- 157.Shi L, Xue J, Zhao W, Wei X, Zhang M, Li L, et al. The prognosis of diabetic foot ulcer is independent of age? a comparative analysis of the characteristics of patients with diabetic foot ulcer in different age groups: A cross-sectional study from China. *Int J Low Extrem Wounds.* 2022;15347346221125844. DOI:10.1177/15347346221125844
- 158.Silva JC, Pitta MGR, Pitta IR, Koh TJ, Abdalla DSP. New peroxisome proliferator-activated receptor agonist (GQ-11) improves wound healing in diabetic mice. *Adv Wound Care (New Rochelle).* 2019;8(9):417-28. DOI:10.1089/wound.2018.0911
- 159.Simsir IY, Sengoz Coskun NS, Akcay YY, Cetinkalp S. The relationship between blood hypoxia-inducible factor-1 α , fetuin-A, fibrinogen, homocysteine, and amputation level. *Int J Low Extrem Wounds.* 2022;21(4):405-13. DOI:10.1177/1534734620948342
- 160.Spoer DL, Shin SE, Kim KG, Haffner ZK, Linnartz KS, Attinger CE, et al. Perioperative evaluation of nutritional status to predict complications in patients with major lower extremity amputation. *Wounds.* 2023;35(3):59-65. DOI:10.25270/wnds/22070
- 161.Spreadborough PJ, Strong AL, Mares J, Levi B, Davis TA. Tourniquet use following blast-associated complex lower limb injury and traumatic amputation promotes end organ dysfunction and amplified heterotopic ossification formation. *J Orthop Surg Res.* 2022;17(1):422. DOI:10.1186/s13018-022-03321-z
- 162.Squiers JJ, Thatcher JE, Bastawros DS, Applewhite AJ, Baxter RD, Yi F, et al. Machine learning analysis of multispectral imaging and clinical risk factors to predict amputation wound healing. *J Vasc Surg.* 2022;75(1):279-85. DOI:10.1016/j.jvs.2021.06.478
- 163.Strong AL, Spreadborough PJ, Dey D, Yang P, Li S, Lee A, et al. BMP Ligand Trap ALK3-Fc Attenuates osteogenesis and heterotopic ossification in blast-related lower extremity trauma. *Stem Cells Dev.* 2021;30(2):91-105. DOI:10.1089/scd.2020.0162
- 164.Sun H, Yang C, Liu X, Liang J, Geng H. Effectiveness of negative pressure wound therapy of diabetic foot ulcers using Periplaneta Americana (Kangfuxin liquid) irrigation. *Int J Low Extrem Wounds.* 2023;15347346231176917. DOI:10.1177/15347346231176917
- 165.Sun X, Wang X, Zhao Z, Chen J, Li C, Zhao G. Paeoniflorin accelerates foot wound healing in diabetic rats through activating the Nrf2 pathway. *Acta Histochemica.* 2020;122(8):151649. DOI:10.1016/j.acthis.2020.151649
- 166.Tan SS, Yeo XY, Liang ZC, Sethi SK, Tay SSW. Stromal vascular fraction promotes fibroblast migration and cellular viability in a hyperglycemic microenvironment through up-regulation of wound healing cytokines. *Exp Mol Pathol.* 2018;104(3):250-5. DOI:10.1016/j.yexmp.2018.03.007
- 167.Tan WS, Arulselvan P, Ng SF, Mat Taib CN, Sarian MN, Fakurazi S. Improvement of diabetic wound healing by topical application of Vicenin-2 hydrocolloid film on Sprague Dawley rats. *BMC Complement Altern Med.* 2019;19(1):20. DOI:10.1186/s12906-018-2427-y
- 168.Tanaka K, Tanaka S, Okazaki J, Mii S. Preoperative nutritional status is independently associated with wound healing in patients undergoing open surgery for ischemic tissue loss. *Vascular.* 2021;29(6):897-904. DOI:10.1177/1708538120980216
- 169.Ugwu E, Adeleye O, Gezawa I, Okpe I, Enamino M, Ezeani I. Predictors of lower extremity amputation in patients with diabetic foot ulcer: findings from MEDFUN, a multi-center observational study. *J Foot Ankle Res.* 2019;12:34. DOI:10.1186/s13047-019-0345-y
- 170.Vangaveti VN, Jhamb S, Hayes O, Goodall J, Bulbrook J, Robertson K, et al. Effects of vildagliptin on wound healing and markers of inflammation in patients with type 2 diabetic foot ulcer: a prospective, randomized, double-blind, placebo-controlled, single-center study. *Diabetol Metab Syndr.* 2022;14(1):183. DOI:10.1186/s13098-022-00938-2
- 171.Vatankhah N, Jahangiri Y, Landry GJ, McLafferty RB, Alkayed NJ, Moneta GL, et al. Predictive value of neutrophil-to-lymphocyte ratio in diabetic wound healing. *J Vasc Surg.* 2017;65(2):478-83. DOI:10.1016/j.jvs.2016.08.108
- 172.Vieceli Dalla Sega F, Cimaglia P, Manfrini M, Fortini F, Marracino L, Bernucci D, et al. Circulating biomarkers of endothelial dysfunction and inflammation in predicting clinical outcomes in

- diabetic patients with critical limb ischemia. *Int J Mol Sci.* 2022;23(18). DOI:10.3390/ijms231810641
173. Walsh SA, Davis TA. Key early proinflammatory signaling molecules encapsulated within circulating exosomes following traumatic injury. *J Inflamm (Lond).* 2022;19(1):6. DOI:10.1186/s12950-022-00303-0
174. Wang H, Wang X, Liu X, Zhou J, Yang Q, Chai B, et al. miR-199a-5p Plays a pivotal role on wound healing via suppressing vegfa and rock1 in diabetic ulcer foot. *Oxid Med Cell Longev.* 2022;2022:4791059. DOI:10.1155/2022/4791059
175. Wang J, Tinney D, Grynshyn M, Pickering JG, Power A, Dubois L, et al. Microcirculation surrounding end-stage human chronic skin wounds is associated with endoglin/CD146/ALK-1 expression, endothelial cell proliferation and an absence of p16(Ink4a). *Wound Repair Regen.* 2023;31(3):321-37. DOI:10.1111/wrr.13081
176. Wang T, Fan L, Liu J, Tao Y, Li X, Wang X, et al. Negative pressure wound therapy promotes wound healing by inhibiting inflammation in diabetic foot wounds: A role for NOD1 receptor. *Int J Low Extrem Wounds.* 2022;15347346221131844. DOI:10.1177/15347346221131844
177. Wu M, Yu Z, Matar DY, Karvar M, Chen Z, Ng B, et al. Human amniotic membrane promotes angiogenesis in an oxidative stress chronic diabetic murine wound model. *Adv Wound Care (New Rochelle).* 2023;12(6):301-15. DOI:10.1089/wound.2022.0005
178. Xiang X, Chen J, Jiang T, Yan C, Kang Y, Zhang M, et al. Milk-derived exosomes carrying siRNA-KEAP1 promote diabetic wound healing by improving oxidative stress. *Drug Deliv Transl Res.* 2023;13(9):2286-96. DOI:10.1007/s13346-023-01306-x
179. Xu S, Wang Y, Hu Z, Ma L, Zhang F, Liu P. Effects of neutrophil-to-lymphocyte ratio, serum calcium, and serum albumin on prognosis in patients with diabetic foot. *Int Wound J.* 2022;20. DOI:10.1111/iwj.14019
180. Yan J, Tie G, Wang S, Tutto A, DeMarco N, Khair L, et al. Diabetes impairs wound healing by Dnm1-dependent dysregulation of hematopoietic stem cells differentiation towards macrophages. *Nat Commun.* 2018;9(1):33. DOI:10.1038/s41467-017-02425-z
181. Yang S, Gu Z, Lu C, Zhang T, Guo X, Xue G, et al. Neutrophil extracellular traps are markers of wound healing impairment in patients with diabetic foot ulcers treated in a multidisciplinary setting. *Adv Wound Care (New Rochelle).* 2020;9(1):16-27. DOI:10.1089/wound.2019.0943
182. Yang SL, Zhu LY, Han R, Sun LL, Dou JT. Effect of negative pressure wound therapy on cellular fibronectin and transforming growth factor- β 1 expression in diabetic foot wounds. *Foot Ankle Int.* 2017;38(8):893-900. DOI:10.1177/1071100717704940
183. Yang X, Mathis BJ, Huang Y, Li W, Shi Y. KLF4 Promotes diabetic chronic wound healing by suppressing Th17 cell differentiation in an MDSC-dependent manner. *J Diabetes Res.* 2021;2021:7945117. DOI:10.1155/2021/7945117
184. Yang Y, Hu H, Wang W, Duan X, Luo S, Wang X, et al. The identification of functional proteins from amputated lumbricus *Eisenia fetida* on the wound healing process. *Biomed Pharmacother.* 2017; 95:1469-78. DOI:10.1016/j.biopha.2017.09.049
185. Yu XT, Wang F, Ding JT, Cai B, Xing JJ, Guo GH, et al. Tandem mass tag-based serum proteomic profiling revealed diabetic foot ulcer pathogenesis and potential therapeutic targets. *Bioengineered.* 2022;13(2):3171-82. DOI:10.1080/21655979.2022.2027173
186. Yuniati R, Innelya I, Rachmawati A, Charlex HJM, Rahmatika A, Khrisna MB, et al. Application of topical sucralfate and topical platelet-rich plasma improves wound healing in diabetic ulcer Rats Wound Model. *J Exp Pharmacol.* 2021;13:797-806. DOI:10.2147/jep.S296767
187. Zhang F, Liu Y, Wang S, Yan X, Lin Y, Chen D, et al. Interleukin-25-mediated-IL-17RB upregulation promotes cutaneous wound healing in diabetic mice by improving endothelial cell functions. *Front Immunol.* 2022;13:809755. DOI:10.3389/fimmu.2022.809755
188. Zhang M, Zhang R, Li X, Cao Y, Huang K, Ding J, et al. CD271 promotes STZ-induced diabetic wound healing and regulates epidermal stem cell survival in the presence of the pTrkA receptor. *Cell Tissue Res.* 2020;379(1):181-93. DOI:10.1007/s00441-019-03125-4
189. Zhang S, Wang S, Xu L, He Y, Xiang J, Tang Z. Clinical outcomes of transtatarsal amputation in patients with diabetic foot ulcers treated without revascularization. *Diabetes Ther.* 2019;10(4):1465-72. DOI:10.1007/s13300-019-0653-z
190. Zhang Y, Jiang W, Kong L, Fu J, Zhang Q, Liu H. PLGA@IL-8 nanoparticles-loaded acellular dermal matrix as a delivery system for exogenous MSCs in diabetic wound healing. *Int J Biol Macromol.* 2023;224:688-98. DOI:10.1016/j.ijbiomac.2022.10.157
191. Zhao Y, Luo L, Huang L, Zhang Y, Tong M, Pan H, et al. In situ hydrogel capturing nitric oxide microbubbles accelerates the healing of diabetic foot. *J Control Release.* 2022;350:93-106. DOI:10.1016/j.jconrel.2022.08.018
192. Zhao Y, Wang X, Yang S, Song X, Sun N, Chen C, et al. Kanglexin accelerates diabetic wound healing by promoting angiogenesis via FGFR1/ERK signaling. *Biomed Pharmacother.* 2020;132:110933. DOI:10.1016/j.biopha.2020.110933
193. Zheng Z, Liu Y, Yang Y, Tang J, Cheng B. Topical 1% propranolol cream promotes cutaneous wound healing in spontaneously diabetic mice. *Wound Repair Regen.* 2017;25(3):389-97. DOI:10.1111/wrr.12546
194. Zhu Z, Wang L, Peng Y, Xiaoying C, Zhou L, Jin Y, et al. Continuous self-oxygenated double-layered hydrogel under natural light for real-time infection monitoring, enhanced photodynamic therapy, and hypoxia relief in refractory diabetic wounds healing. *Adv Funct Mater.* 2022;32. DOI:10.1002/adfm.202201875
195. Al-Shibly I, Alhmdany M, Al-Kaif R, Al-Kaif L. Immunological base behind the increased susceptibility of diabetic patients for infections. *Indian J Public Health Res Dev.* 2019;10:3047. DOI:10.5958/0976-5506.2019.03343.6
196. Di Cristo F, Valentino A, De Luca I, Peluso G, Bonadies I, Di Salle A, et al. Polylactic acid/poly(vinylpyrrolidone) co-electrospun fibrous membrane as a tunable quercetin delivery platform for diabetic wounds. *Pharmaceutics.* 2023;15(3). DOI:10.3390/pharmaceutics15030805

197. Dur-E-Sameen M, Msskkhkmsiazk. Exploring association of anemia with diabetic foot ulcer and its impact on disease outcome in a tertiary care hospital. *Pak J Med Health Sci.* 2023;16(12):406. DOI:10.53350/pjmhs20221612406
198. García-Ojalvo A, Berlanga Acosta J, Figueroa-Martínez A, Béquet-Romero M, Mendoza-Mari Y, Fernández-Mayola M, et al. Systemic translation of locally infiltrated epidermal growth factor in diabetic lower extremity wounds. *Int Wound J.* 2019;16(6):1294-303. DOI:10.1111/iwj.13189
199. Izadi M, Kheirjou R, Mohammadpour R, Aliyoldashi MH, Moghadam SJ, Khorvash F, et al. Efficacy of comprehensive ozone therapy in diabetic foot ulcer healing. *Diabetes Metab Syndr.* 2019;13(1):822-5. DOI:10.1016/j.dsx.2018.11.060
200. Kapukaya R, Kapukaya A, Keklikcioglu B, Özdemir AA. How important are mean platelet volume and neutrophil values in diabetic foot amputation decision? *Eur J Plast Surg.* 2021;44(4):507-10. DOI:10.1007/s00238-020-01773-2
201. Kim JH, Ruegger PR, Lebig EG, VanSchalkwyk S, Jeske DR, Hsiao A, et al. High levels of oxidative stress create a microenvironment that significantly decreases the diversity of the microbiota in diabetic chronic wounds and promotes biofilm formation. *Front Cell Infect Microbiol.* 2020;10:259. DOI:10.3389/fcimb.2020.00259
202. Nguyen TT, Jones JI, Wolter WR, Pérez RL, Schroeder VA, Champion MM, et al. Hyperbaric oxygen therapy accelerates wound healing in diabetic mice by decreasing active matrix metalloproteinase-9. *Wound Repair Regen.* 2020;28(2):194-201. DOI:10.1111/wrr.12782
203. Ojalvo AG, Acosta JB, Mari YM, Mayola MF, Pérez CV, Gutiérrez WS, et al. Healing enhancement of diabetic wounds by locally infiltrated epidermal growth factor is associated with systemic oxidative stress reduction. *Int Wound J.* 2017;14(1):214-25. DOI:10.1111/iwj.12592
204. Oley MH, Oley MC, Noersasongko AD, Hatta M, Phillips GG, Agustine, et al. Effects of hyperbaric oxygen therapy on vascular endothelial growth factor protein and mRNA in crush injury patients: A randomized controlled trial study. *Int J Surg Open.* 2021;29:33-9. DOI:10.1016/j.ijso.2021.01.003
205. Oley MH, Oley MC, Tjandra DE, Sedu SW, Sumarawu ERN, Aling DMR, et al. Hyperbaric oxygen therapy in the healing process of foot ulcers in diabetic type 2 patients marked by interleukin 6, vascular endothelial growth factor, and PEDIS score: A randomized controlled trial study. *Int J Surg Open.* 2020;27:154-61. DOI:10.1016/j.ijso.2020.11.012
206. Shang W, Chen G, Li Y, Zhuo Y, Wang Y, Fang Z, et al. Static magnetic field accelerates diabetic wound healing by facilitating resolution of inflammation. *J Diabetes Res.* 2019;2019:5641271. DOI:10.1155/2019/5641271
207. Chen CY, Wu RW, Hsu MC, Hsieh CJ, Chou MC. Adjunctive hyperbaric oxygen therapy for healing of chronic diabetic foot ulcers: A randomized controlled trial. *J Wound Ostomy Continence Nurs.* 2017;44(6):536-45. DOI:10.1097/won.0000000000000374
208. Chen J, Bao X, Meng T, Sun J, Yang X. Zeolitic imidazolate framework-67 accelerates infected diabetic chronic wound healing. *Chem Eng J.* 2022;430:133091. DOI:10.1016/j.cej.2021.133091
209. Chen Z, Haus JM, DiPietro LA, Koh TJ, Minshall RD. Neutralization of excessive CCL28 improves wound healing in diabetic mice. *Front Pharmacol.* 2023;14:1087924. DOI:10.3389/fphar.2023.1087924
210. Chiang N, Rodda OA, Sleight J, Vasudevan T. Effects of topical negative pressure therapy on tissue oxygenation and wound healing in vascular foot wounds. *J Vasc Surg.* 2017;66(2):564-71. DOI:10.1016/j.jvs.2017.02.050
211. Derakhshandeh H, Aghabaglou F, McCarthy A, Mostafavi A, Wiseman C, Bonick Z, et al. A wirelessly controlled smart bandage with 3d-printed miniaturized needle arrays. *Adv Funct Mater.* 2020;30(13). DOI:10.1002/adfm.201905544
212. Gao S, Chen T, Wang Z, Ji P, Xu L, Cui W, et al. Immuno-activated mesenchymal stem cell living electrospun nanofibers for promoting diabetic wound repair. *J Nanobiotechnology.* 2022;20(1):294. DOI:10.1186/s12951-022-01503-9
213. Greene CJ, Anderson S, Barthels D, Howlader MSI, Kanji S, Sarkar J, et al. DPSC products accelerate wound healing in diabetic mice through induction of SMAD molecules. *Cells.* 2022;11(15). DOI:10.3390/cells11152409
214. Hassan RF, Kadhim HM. Comparative effects of phenolic extract as an ointment dosage form in inducing wound healing in mice and β -sitosterol in experimentally induced acute wound healing in mice. *J Pharm Negat Results.* 2022;13(3):194-203. DOI:10.47750/pnr.2022.13.03.031
215. Jing S, Li H, Xu H. Mesenchymal stem cell derived exosomes therapy in diabetic wound repair. *Int J Nanomedicine.* 2023;18:2707-20. DOI:10.2147/ijn.S411562
216. Kanji S, Das M, Joseph M, Aggarwal R, Sharma SM, Ostrowski M, et al. Nanofiber-expanded human CD34(+) cells heal cutaneous wounds in streptozotocin-induced diabetic mice. *Sci Rep.* 2019;9(1):8415. DOI:10.1038/s41598-019-44932-7
217. Kevin L, Jagadeesh M, Priscilla L, Kacie K, Richard S, Edwin R, et al. Oxygenation based perfusion assessment of diabetic foot ulcers using a breath-hold paradigm. *ProcSPIE.* 2019;10873:1087304. DOI:10.1117/12.2509917
218. Li X, Xie X, Lian W, Shi R, Han S, Zhang H, et al. Exosomes from adipose-derived stem cells overexpressing Nrf2 accelerate cutaneous wound healing by promoting vascularization in a diabetic foot ulcer rat model. *Exp Mol Med.* 2018;50(4):1-14. DOI:10.1038/s12276-018-0058-5
219. Liu C, Teo MHY, Pek SLT, Wu X, Leong ML, Tay HM, et al. A multifunctional role of leucine-rich α -2-glycoprotein 1 in cutaneous wound healing under normal and diabetic conditions. *Diabetes.* 2020;69(11):2467-80. DOI:10.2337/db20-0585
220. Morisaki K, Yamaoka T, Iwasa K. Risk factors for wound complications and 30-day mortality after major lower limb amputations in patients with peripheral arterial disease. *Vascular.* 2018;26(1):12-7. DOI:10.1177/1708538117714197
221. Nolan GS, Smith OJ, Heavey S, Jell G, Mosahebi A. Histological analysis of fat grafting with platelet-rich plasma for diabetic foot ulcers-A randomised controlled trial. *Int Wound J.* 2022;19(2):389-98. DOI:10.1111/iwj.13640

222. Nur Rosyid F, Dharmana E, Suwondo A, Hs K, Sugiarto S. The effect of bitter melon (*Momordica Charantia* L.) leaves extract on TNF- α serum levels and diabetic foot ulcers improvement: Randomized controlled trial. *Biomed Pharmacol J.* 2018;11:1413-21. DOI:10.13005/bpj/1505
223. Paul TS, Das BB, Talekar YP, Banerjee S. Exploration of the role of a lithophytic fern, *Pteris vittata* L. in wound tissue regeneration and remodelling of genes in hyperglycaemic rat model. *Clinical Phytoscience.* 2020;6(1):79. DOI:10.1186/s40816-020-00223-7
224. Pu D, Lei X, Leng W, Zheng Y, Chen L, Liang Z, et al. Lower limb arterial intervention or autologous platelet-rich gel treatment of diabetic lower extremity arterial disease patients with foot ulcers. *Ann Transl Med.* 2019;7(18):485. DOI:10.21037/atm.2019.07.87
225. Ramaprabha P, Ramani CP, Kesavan R. Study on microbiome of chronic non healing diabetic ulcers with special reference to biofilm and multidrug resistant strains. *J Clin Diagn Res.* 2021. DOI:10.7860/JCDR/2021/50126.15471
226. Tellechea A, Bai S, Dangwal S, Theocharidis G, Nagai M, Koerner S, et al. Topical application of a mast cell stabilizer improves impaired diabetic wound healing. *J Invest Dermatol.* 2020;140(4):901-11.e11. DOI:10.1016/j.jid.2019.08.449
227. Tkaczyk C, Jones-Nelson O, Shi YY, Tabor DE, Cheng L, Zhang T, et al. Neutralizing staphylococcus aureus virulence with AZD6389, a three mab combination, accelerates closure of a diabetic polymicrobial wound. *mSphere.* 2022;7(3):e0013022. DOI:10.1128/msphere.00130-22
228. Trejo J, Ryan E, Khan F, Iannuzzi N, Chansky H, Lack WD. Risk factors for failure of limb salvage among veterans with foot ulcers. *Foot Ankle Surg.* 2022;28(5):584-7. DOI:10.1016/j.fas.2021.06.003
229. Wang T, Zheng Y, Shi Y, Zhao L. pH-responsive calcium alginate hydrogel laden with protamine nanoparticles and hyaluronan oligosaccharide promotes diabetic wound healing by enhancing angiogenesis and antibacterial activity. *Drug Deliv Transl Res.* 2019;9(1):227-39. DOI:10.1007/s13346-018-00609-8
230. Wu T, Xie D, Zhao X, Xu M, Luo L, Deng D, et al. Enhanced expression of miR-34c in peripheral plasma associated with diabetic foot ulcer in type 2 diabetes patients. *Diabetes Metab Syndr Obes.* 2021;14:4263-73. DOI:10.2147/dms.o.S326066
231. Xia G, Liu Y, Tian M, Gao P, Bao Z, Bai X, et al. Nanoparticles/thermosensitive hydrogel reinforced with chitin whiskers as a wound dressing for treating chronic wounds. *J Mater Chem B.* 2017;5(17):3172-85. DOI:10.1039/c7tb00479f
232. Yadav S, Arya DK, Pandey P, Anand S, Gautam AK, Ranjan S, et al. ECM mimicking biodegradable nanofibrous scaffold enriched with Curcumin/ZnO to accelerate diabetic wound healing via multifunctional bioactivity. *Int J Nanomedicine.* 2022;17:6843-59. DOI:10.2147/ijn.S388264
233. Ye J, Kang Y, Sun X, Ni P, Wu M, Lu S. MicroRNA-155 inhibition promoted wound healing in diabetic rats. *Int J Low Extrem Wounds.* 2017;16(2):74-84. DOI:10.1177/1534734617706636
234. Zubair M, Ahmad J. Transcutaneous oxygen pressure (TcPO₂) and ulcer outcome in diabetic patients: Is there any correlation? *Diabetes Metab Syndr.* 2019;13(2):953-8. DOI:10.1016/j.dsx.2018.12.008
235. Baumfeld D, Baumfeld T, Macedo B, Zambelli R, Lopes F, Nery C. Factors related to amputation level and wound healing in diabetic patients. *Acta Ortop Bras.* 2018;26(5):342-5. DOI:10.1590/1413-785220182605173445
236. Camacho-Rodríguez H, Guillen-Pérez IA, Roca-Campaña J, Baldomero-Hernández JE, Tuero-Iglesias Á D, Galván-Cabrera JA, et al. Heberprot-P's effect on gene expression in healing diabetic foot ulcers. *Medic Rev.* 2018;20(3):10-4. DOI:10.37757/mr2018.V20.N3.4
237. Khan MS, Tauqeer Ahmed M. Novel candidates for chronic diabetic wound healing. *J Pak Assoc Dermatol.* 2022;32(3):526-31.
238. Naderi N, Zaefizadeh M. Expression of growth factors in re-epithelialization of diabetic foot ulcers after treatment with non-thermal plasma radiation. *Biomedical Research (India).* 2017;28:3402-7
239. Salih K, Faraj YF, Mohammed I. Salivary matrix metalloproteinase-8 indicate the severity of diabetic foot ulcer. *Int J Biochem Cell Biol.* 2020;18:1543-8
240. Van Den Hoven P, Van Den Berg SD, Van Der Valk JP, Van Der Krogt H, Van Doorn LP, Van De Bogt KEA, et al. Assessment of tissue viability following amputation surgery using near-infrared fluorescence imaging with indocyanine green. *Ann Vasc Surg.* 2022;78:281-7. DOI:10.1016/j.avsg.2021.04.030
241. Viswanathan V, Juttada U, Babu M. Efficacy of recombinant human epidermal growth factor (Regen-D 150) in healing diabetic foot ulcers: A hospital-based randomized controlled trial. *Int J Low Extrem Wounds.* 2020;19(2):158-64. DOI:10.1177/1534734619892791
242. Zahid AA, Ahmed R, Ur Rehman SR, Augustine R, Hasan A. Reactive nitrogen species releasing hydrogel for enhanced wound healing. *Annu Int Conf IEEE Eng Med Biol Soc.* 2019;2019:3939-42. DOI:10.1109/embc.2019.8856469
243. Eyth E, Naik R. Hemoglobin A1C. [Internet]. Treasure Island (FL): StatPearls Publishing; 2023; [cited 2024, July 5]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK549816/>
244. Toth M, Fridman R. Assessment of gelatinases (MMP-2 and MMP-9) by gelatin zymography. *Methods Mol Med.* 2001;57:163-74. DOI:10.1385/1-59259-136-1:163
245. Alhajj M, Zubair M, Farhana A. Enzyme-linked immunosorbent assay [Internet]. Treasure Island (FL): StatPearls Publishing; 2023; [cited 2024, July 5]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK555922/>
246. Ahsan H. Monoplex and multiplex immunoassays: Approval, advancements, and alternatives. *Comp Clin Path.* 2022;31(2):333-45. DOI:10.1007/s00580-021-03302-4
247. National Library of Medicine. Real-time qRT-PCR [Internet]. Bethesda (MD): National Library of Medicine; [cited 2024, July 5]. Available from: <https://www.ncbi.nlm.nih.gov/probe/docs/techqpcr/>
248. Nature Education. Western blot [Internet]. 2014; [cited 2024, July 5]. Available from: <https://www.nature.com/scitable/definition/western-blot-288/>

- 249.Chen M, Calin GA, Meng QH. Circulating microRNAs as promising tumor biomarkers. *Adv Clin Chem.* 2014;67:189-214. DOI:10.1016/bs.acc.2014.09.007
- 250.Kralik P, Ricchi M. A basic guide to real time PCR in microbial diagnostics: Definitions, parameters, and everything. *Front Microbiol.* 2017;8:108. DOI:10.3389/fmicb.2017.00108
- 251.Idleburg C, Lorenz MR, DeLassus EN, Scheller EL, Veis DJ. Immunostaining of skeletal tissues. *Methods Mol Biol.* 2021;2221:261-73. DOI:10.1007/978-1-0716-0989-7_15
- 252.Zielonka J, Lambeth JD, Kalyanaraman B. On the use of L-012, a luminol-based chemiluminescent probe, for detecting superoxide and identifying inhibitors of NADPH oxidase: A reevaluation. *Free Radic Biol Med.* 2013;65:1310-4. DOI:10.1016/j.freeradbiomed.2013.09.017
- 253.Tawa M, Okamura T. Factors influencing the soluble guanylate cyclase heme redox state in blood vessels. *Vascular Pharmacology.* 2022;145:107023. DOI:10.1016/j.vph.2022.107023
- 254.Justiz Vaillant AA, Qurie A. Interleukin [Internet]. Treasure Island (FL): StatPearls Publishing; 2024; [cited 2024, July 5]. Available from: <http://www.ncbi.nlm.nih.gov/books/nbk499840/>
- 255.Doersch KM, DelloStitto DJ, Newell-Rogers MK. The contribution of interleukin-2 to effective wound healing. *Exp Biol Med (Maywood).* 2017;242(4):384-96. DOI:10.1177/1535370216675773
- 256.Canchy L, Kerob D, Demessant A, Amici JM. Wound healing and microbiome, an unexpected relationship. *J Eur Acad Dermatol Venereol.* 2023;37 Suppl 3:7-15. DOI:10.1111/jdv.18854
- 257.Christman AL, Selvin E, Margolis DJ, Lazarus GS, Garza LA. Hemoglobin A1c predicts healing rate in diabetic wounds. *J Invest Dermatol.* 2011;131(10):2121-7. DOI:10.1038/jid.2011.176
- 258.Lin PH, Sermersheim M, Li H, Lee PHU, Steinberg SM, Ma J. Zinc in wound healing modulation. *Nutrients.* 2017;10(1). DOI:10.3390/nu10010016
- 259.Ghaly P, Iliopoulos J, Ahmad M. The role of nutrition in wound healing: an overview. *Br J Nurs.* 2021;30(5):S38-s42. DOI:10.12968/bjon.2021.30.5.S38
- 260.Zinc Sulfate Administered Orally; Wounds Reported To Heal Faster. *JAMA.* 1966;196(10):33-4. DOI:10.1001/jama.1966.03100230015004
- 261.Carr R, Heberton J, Davie-Smith F. A survey of the lower limb amputee population in Scotland 2019 public report. 2022; [cited 2024, July 5]. Available from: [https://www.bacpar.org/data/Resource_Downloads/SPARGReport2019\(Public\).pdf](https://www.bacpar.org/data/Resource_Downloads/SPARGReport2019(Public).pdf)
- 262.Johnson KE, Wilgus TA. Vascular endothelial growth factor and angiogenesis in the regulation of cutaneous wound repair. *Adv Wound Care (New Rochelle).* 2014;3(10):647-61. DOI:10.1089/wound.2013.0517
- 263.Darby I, Skalli O, Gabbiani G. Alpha-smooth muscle actin is transiently expressed by myofibroblasts during experimental wound healing. *Lab Invest.* 1990;63(1):21-9
- 264.Darby IA, Laverdet B, Bonté F, Desmoulière A. Fibroblasts and myofibroblasts in wound healing. *Clin Cosmet Investig Dermatol.* 2014;7:301-11. DOI:10.2147/ccid.S50046
- 265.Mank V, Azhar W, Brown K. Leukocytosis [Internet]. Treasure Island (FL): StatPearls Publishing; 2024; [cited 2024, July 5]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK560882/>
- 266.Gouin JP, Kiecolt-Glaser JK. The impact of psychological stress on wound healing: Methods and mechanisms. *Immunol Allergy Clin North Am.* 2011;31(1):81-93. DOI:10.1016/j.jiac.2010.09.010
- 267.Turgeon NA, Perez S, Mondestin M, Davis SS, Lin E, Tata S, et al. The impact of renal function on outcomes of bariatric surgery. *J Am Soc Nephrol.* 2012;23(5):885-94. DOI:10.1681/asn.2011050476
- 268.Lind J, Kramhøft M, Bødtker S. The influence of smoking on complications after primary amputations of the lower extremity. *Clin Orthop Relat Res.* 1991(267):211-7
- 269.Silverstein P. Smoking and wound healing. *Am J Med.* 1992;93(1a):22s-4s. DOI:10.1016/0002-9343(92)90623-j
- 270.Jung MK, Callaci JJ, Lauing KL, Otis JS, Radek KA, Jones MK, et al. Alcohol exposure and mechanisms of tissue injury and repair. *Alcohol Clin Exp Res.* 2011;35(3):392-9. DOI:10.1111/j.1530-0277.2010.01356.x
- 271.Zhou J, Tsai YT, Weng H, Tang L. Noninvasive assessment of localized inflammatory responses. *Free Radic Biol Med.* 2012;52(1):218-26. DOI:10.1016/j.freeradbiomed.2011.10.452
- 272.Nehring SM, Goyal A, Patel BC. C-reactive protein [Internet]. Treasure Island (FL): StatPearls Publishing; 2024; [cited 2024, July 5]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK441843/>
- 273.NHS. Examples of blood tests [Internet]. NHS; 2022; [updated 2022 Aug 8; cited 2024, July 5]. Available from: <https://www.nhs.uk/conditions/blood-tests/types/>
- 274.Collaborators GD. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: A systematic analysis for the global burden of disease study 2021. *Lancet.* 2023;402(10397):203-34. DOI:10.1016/s0140-6736(23)01301-6
- 275.Oliver TI, Mutluoglu M. Diabetic Foot Ulcer [Internet]. In: StatPearls. Treasure Island, Florida: StatPearls Publishing. [cited 2024, July 5]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK537328/>
- 276.Lin C, Liu J, Sun H. Risk factors for lower extremity amputation in patients with diabetic foot ulcers: A meta-analysis. *PLoS One.* 2020;15(9):e0239236. DOI:10.1371/journal.pone.0239236
- 277.Lu Q, Wang J, Wei X, Wang G, Xu Y. Risk factors for major amputation in diabetic foot ulcer patients. *Diabetes Metab Syndr Obes.* 2021;14:2019-27. DOI:10.2147/dms0.S307815
- 278.Yazdanyar A, Newman AB. The burden of cardiovascular disease in the elderly: Morbidity, mortality, and costs. *Clin Geriatr Med.* 2009;25(4):563-77, vii. DOI:10.1016/j.cger.2009.07.007

279. Van Langevelde K, Srámek A, Rosendaal FR. The effect of aging on venous valves. *Arterioscler Thromb Vasc Biol.* 2010;30(10):2075-80. DOI:10.1161/atvbaha.110.209049

280. Margolis DJ, Knauss J, Bilker W, Baumgarten M. Medical conditions as risk factors for pressure ulcers in an outpatient setting. *Age Ageing.* 2003;32(3):259-64. DOI:10.1093/ageing/32.3.259

281. England PH. Diabetes Prevalence Model [Internet]. London. 2016; [cited 2024, July 5]. Available from: <https://assets.publishing.service.gov.uk/media/5a82c07340f0b6230269c82d/Diabetesprevalencemodelbriefing.pdf>

282. Tas U, Verhagen AP, Bierma-Zeinstra SM, Odling E, Koes BW. Prognostic factors of disability in older people: A systematic review. *Br J Gen Pract.* 2007;57(537):319-23

283. Khalid KA, Nawi AFM, Zulkifli N, Barkat MA, Hadi H. Aging and wound healing of the skin: A review of clinical and pathophysiological hallmarks. *Life (Basel).* 2022;12(12). DOI:10.3390/life12122142

284. Zhang H, Huang C, Bai J, Wang J. Effect of diabetic foot ulcers and other risk factors on the prevalence of lower extremity amputation: A meta-analysis. *Int Wound J.* 2023;20(8):3035-47. DOI:10.1111/iwj.14179

285. Vanherwegen AS, Lauwers P, Lavens A, Doggen K, Dirinck E. Sex differences in diabetic foot ulcer severity and outcome in Belgium. *PLoS One.* 2023;18(2):e0281886. DOI:10.1371/journal.pone.0281886

286. Offner PJ, Moore EE, Biffl WL. Male gender is a risk factor for major infections after surgery. *Arch Surg.* 1999;134(9):935-8; discussion 8-40. DOI:10.1001/archsurg.134.9.935

287. Pape M, Giannakópoulos GF, Zuidema WP, de Lange-Klerk ESM, Toor EJ, Edwards MJR, et al. Is there an association between female gender and outcome in severe trauma? A multi-center analysis in the Netherlands. *Scand J Trauma Resusc Emerg Med.* 2019;27(1):16. DOI:10.1186/s13049-019-0589-3

288. Use of both sexes to be default in laboratory experimental design [Internet]. UK Research and Innovation (UKRI). 2022; [cited 2024, July 5]. Available from: <https://www.ukri.org/news/use-of-both-sexes-to-be-default-in-laboratory-experimental-design/>

289. Lindley LE, Stojadinovic O, Pastar I, Tomic-Canic M. Biology and biomarkers for wound healing. *Plast Reconstr Surg.* 2016;138(3 Suppl):18s-28s. DOI:10.1097/prs.0000000000002682

290. Bracken MB. Why animal studies are often poor predictors of human reactions to exposure. *J R Soc Med.* 2009;102(3):120-2. DOI:10.1258/jrsm.2008.08k033

291. Afzal A, Saleel CA, Bhattacharyya S, Satish N, Samuel OD, Badruddin IA. Merits and limitations of mathematical modeling and computational simulations in mitigation of COVID-19 pandemic: A comprehensive review. *Arch Comput Methods Eng.* 2022;29(2):1311-37. DOI:10.1007/s11831-021-09634-2

292. White A, Tolman M, Thames HD, Withers HR, Mason KA, Transtrum MK. The Limitations of model-based experimental design and parameter estimation in sloppy systems. *PLoS Comput Biol.* 2016;12(12):e1005227. DOI:10.1371/journal.pcbi.1005227

293. Menon SN, Flegg JA. Mathematical modeling can advance wound healing research. *Adv Wound Care (New Rochelle).* 2021;10(6):328-44. DOI:10.1089/wound.2019.1132

294. Paez A. Gray literature: An important resource in systematic reviews. *J Evid Based Med.* 2017;10(3):233-40. DOI:10.1111/jebm.12266

Abbreviations & Acronyms:

| Abbreviations & Acronyms | Definition |
|--------------------------|--|
| BLI | Bioluminescence Imaging |
| CCL | Chemokine (C-C motif) Ligand |
| CD | Cluster of Differentiation |
| CRP | C-Reactive Protein |
| DFU | Diabetic Foot Ulcer |
| DNA | Deoxyribonucleic Acid |
| EGF | Epidermal Growth Factor |
| ELISA | Enzyme-Linked Immunosorbent Assay |
| eNOS | Endothelial Nitric Oxide Synthase |
| ERK | Extracellular signal-Regulated Kinase |
| ESR | Erythrocyte Sedimentation Rate |
| FBS | Fasting Blood Sugar |
| Freq. | Frequency |
| FGF | Fibroblast Growth Factor |
| Hb | Hemoglobin |
| HbA1c | Hemoglobin A1C (glycated hemoglobin) |
| HCT | Hematocrit |
| HDL | High-Density Lipoprotein |
| HIF1-α | Hypoxia-Inducible Factor 1 Alpha |
| IFN | Interferon |
| IGF | Insulin-like Growth Factor |
| IL | Interleukin |
| iNOS | Inducible Nitric Oxide Synthase |
| JBI | Joanna Briggs Institute |
| Ki-67 | Antigen Kiel 67 |
| LDL | Low-Density Lipoprotein |
| MCP | Monocyte Chemoattractant Protein |
| MMP | Matrix Metalloproteinases |
| MPO | Myeloperoxidase |
| NA | Not Applicable |
| NADPH | Nicotinamide Adenine Dinucleotide Phosphate |
| NF-κB | Nuclear Factor kappa-light-chain-enhancer of activated B cells |
| No. | Number |
| PDGF | Platelet-Derived Growth Factor |
| PRISMA-ScR | Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews |
| qRT-PCR | Quantitative Reverse Transcription Polymerase Chain Reaction |
| RCT | Randomized Controlled Trial |
| Refs. | References |
| RNA | Ribonucleic Acid |
| ROS | Reactive Oxygen Species |
| SPARG | Scottish Physiotherapy Amputee Research Group |
| TGF | Transforming Growth Factor |
| TIMPs | Tissue Inhibitor of Metalloproteinase |
| TMA | Transmetatarsal amputation |
| TMR® | Therapeutic Magnetic Resonance |
| TNF | Tumor Necrosis Factor |
| USA | United States of America |
| VEGF | Vascular Endothelial Growth Factor |
| WBC | White Blood Cells |
| α-SMA | Alpha-Smooth Muscle Actin |